Centers for Disease Control and Prevention

HIV Prevention Strategic Plan Through 2005

September 2000
CDC’s Goals for HIV Prevention

1. Reduce the number of new HIV infections per year in the United States from an estimated 40,000 to 20,000 per year by 2005.

2. Through voluntary counseling and testing, increase the proportion of HIV-infected people in the United States who know they are infected from the current 70% to 95% by 2005.

3. Increase the proportion of HIV-infected people in the United States who are linked to appropriate care, prevention services and treatment services from the current estimated 50% to 80% by 2005.

4. Reduce HIV transmission and improve HIV/AIDS care and support through partnership with resource-constrained countries.
Table of Contents

Submitting Comments on the Draft Strategic Plan..................................................3
Public meeting dates, times and locations.................................................................4
Acknowledgments.....................................................................................................5
Acronyms..................................................................................................................6
Executive Summary....................................................................................................8
Selected Objectives and Strategies..........................................................................10
Foreword....................................................................................................................15
Goal 1: Reduce the number of new HIV infections per year in the United States from an estimated 40,000 to 20,000 per year by 2005.........................................................28
Goal 2: Through voluntary counseling and testing, increase the proportion of HIV-infected people in the United States who know they are infected from the current 70% to 95% by 2005..................................................................................36
Goal 3: Increase the proportion of HIV-infected people in the United States who are linked to appropriate care, prevention services and treatment services from the current estimated 50% to 80% by 2005.........................................................41
Goal 4: Reduce HIV transmission and improve HIV/AIDS care and support through partnership with resource-constrained countries.................................................50
Appendix A: Background Information on the Strategic Planning Process..............55
Appendix B: Workgroup Members............................................................................57
CDC Is Seeking Your Comments on the Draft HIV Prevention Strategic Plan

CDC invites your comments on the comprehensiveness, clarity, coherence and viability of the draft five-year strategic plan. We are especially interested in learning about any gaps you perceive. The plan is available on CDC’s website (www.cdc.gov) or through the CDC National Prevention Information Network by calling 1-800-458-5231.

If possible, organize your comments using this framework so that we may address them most easily:

- General comments on the overall plan
- Specific comments on Goal 1 and its objectives and strategies
- Specific comments on Goal 2 and its objectives and strategies
- Specific comments on Goal 3 and its objectives and strategies
- Specific comments on Goal 4 and its objectives and strategies
- Comments on priorities

Be sure to include your contact information so that we can let you know about any changes in the plan following the comment period.

Please send your comments postmarked or emailed by October 23, 2000, to:

HIV Prevention Plan Comments  
National Center for HIV, STD, and TB Prevention Centers for Disease Control and Prevention (E07)  
1600 Clifton Road NE  
Atlanta, GA  30333  
USA  
Email address:  hiv.plan.comment@cdc.gov

Comments postmarked or emailed after October 23, 2000, cannot be considered.
Public Meetings on the Draft Strategic Plan

CDC is holding four public meetings to seek comments and input on this draft. The meetings will be held from **1:30-4:30 p.m. local time** on these dates and in these locations:

**Tuesday, Sept. 19, 2000**
- Holiday Inn-Bay Bridge
  - 1800 Powell Street
  - Emeryville, CA 94608
  - 510-658-9300

**Wednesday, Sept. 20, 2000**
- Red Lion
  - 2525 West South Loop
  - Houston, TX 77027
  - 713-961-3000

**Thursday, Sept. 21, 2000**
- Congress Plaza Hotel
  - 520 South Michigan Avenue
  - Chicago, IL 60605
  - 312-427-3800

**Thursday, Sept. 28, 2000**
- Hotel Pennsylvania
  - 410 7th Avenue
  - New York, NY 10001
  - 212-736-5000

The meetings will be open to the public, limited only by the space available. The meeting rooms each accommodate approximately 100 people.
Acknowledgments

The Department of Health and Human Services is developing a comprehensive strategic framework for HIV/AIDS that encompasses the efforts of all the Department’s agencies that conduct HIV/AIDS activities. This draft strategic plan from CDC is one component of that overarching framework. Other DHHS agencies that engage in HIV/AIDS activities (such as the National Institutes of Health and the Health Resources and Services Administration, among others) also have strategic plans, which are part of the Department’s overall effort to combat HIV/AIDS.

CDC is seeking comment broadly, from all its partners, including public sector, private sector and not-for-profit agencies. The comment period on this draft plan ends October 23, 2000. Comments will be considered and the draft plan revised as needed after that time.

CDC gratefully acknowledges the time, effort and expertise of the external consultants and internal CDC staff who helped craft this strategic plan. The members of the four workgroups, corresponding to the four HIV prevention goals, are listed in Appendix B, page 57.

We also recognize the guidance of the agency’s Advisory Committee for HIV and STD Prevention, which was the catalyst for the development of this plan and whose members provided invaluable insights into its refinement.

Finally, we acknowledge the help of the staff of Management Assistance Corporation, who arranged meetings and travel, facilitated workgroup meetings and provided support in the development of this document.
Acronyms

AETC  AIDS Education and Training Center, funded by HRSA
AHRQ  Agency for Healthcare Research and Quality, a DHHS agency that provides information on health care outcomes, quality, cost, use and access
AIDS  Acquired Immunodeficiency Syndrome
AZT  Azidothimidine, a drug used to fight HIV disease; effective at interrupting mother-to-child HIV transmission
CBO  Community-Based Organization
CDC  Centers for Disease Control and Prevention, a DHHS agency, promotes health and quality of life by preventing and controlling disease, injury and disability through partnerships throughout the nation and the world to monitor health, detect and investigate health problems, conduct applied research to enhance prevention, develop and advocate sound public health policies, implement prevention strategies, promote healthy behaviors, foster safe and healthful environments and provide leadership and training
CIOs  The various Centers, Institute and Offices that make up CDC
CPG  Community Planning Group, a local council that determines HIV prevention priorities for state and local health departments funded by CDC
DHHS  Department of Health and Human Services, a U.S. government entity
DOT  Directly Observed Therapy
FDA  Food and Drug Administration, a DHHS agency, assures the safety of foods and cosmetics, and the safety and efficacy of pharmaceuticals, biological products and medical devices, including HIV tests
HAART  Highly Active Anti-Retroviral Treatment, multi-drug treatment for HIV infection
HCFA  Health Care Financing Administration, a DHHS agency, administers the Medicare and Medicaid programs, which provide health insurance to America's aged, poor, disabled and indigenous populations, and the States Children's Health Insurance Program (SCHIP), all of which include people with HIV/AIDS
HE/RR  Health Education/Risk Reduction, an essential component of HIV prevention programs

HIV  Human Immunodeficiency Virus, the virus that causes AIDS

HRSA  Health Resources and Services Administration, a DHHS agency, provides health resources for medically underserved populations; provides services to people with AIDS through the Ryan White CARE Act programs; supports a nationwide network of community and migrant health centers, and primary care programs for the homeless and residents of public housing; builds the health care workforce, maintains the National Health Service Corps, provides AIDS training for health care providers

IDU  Injecting Drug Use, Injecting Drug User

IHS  Indian Health Service, a DHHS agency, provides services to nearly 1.5 million American Indians and Alaska Natives of 557 federally recognized tribes

MSM  Men Who Have Sex with Men

NGO  Non-Governmental Organization

NIH  National Institutes for Health, a DHHS agency, sponsors medical research on diseases like cancer, Alzheimer's, diabetes, arthritis, heart ailments and AIDS

OI  Opportunistic Infection, associated with HIV/AIDS

PCM  Prevention Case Management

SAMHSA  Substance Abuse and Mental Health Services Administration, a DHHS agency, works to improve the quality and availability of substance abuse prevention, addiction treatment and mental health services

SCHIP  States Child Health Insurance Program, administered by HCFA; provides health coverage to children, including those with HIV/AIDS, whose parents are not eligible for Medicaid

STD, STI  Sexually Transmitted Disease, Sexually Transmitted Infection

TB  Tuberculosis

VCT  Voluntary Counseling and Testing for HIV infection
Executive Summary

Because of substantial improvements in early diagnosis and care for people infected with HIV, more Americans are living with HIV than ever before. Individuals and society as a whole are benefiting from this remarkable progress. However, it does mean more opportunities for transmitting the virus and increased needs for HIV prevention. But not all those with HIV are aware of their infection. CDC estimates that 800,000-900,000 people are living with HIV in America, and as many as one third don’t even know they have the virus.

And, despite tremendous successes in HIV prevention over the past decade, the number of new HIV infections each year (incidence) in the United States remains unacceptably high. Although incidence has decreased substantially from the high of 150,000 cases per year in the late 1980s, CDC estimates that some 40,000 Americans become infected with HIV every year, and this has been true since the early 1990s.

As the pie charts below show, the HIV epidemic in America is increasingly affecting communities of color – particularly young people and women. Among men, the majority of new infections, nearly 60%, continue to be among MSM (men who have sex with men). Recent evidence of resurgent unsafe behaviors and outbreaks of other sexually transmitted diseases (such as syphilis and gonorrhea) among MSM underscore the importance of sustaining and improving prevention efforts for this population.

The Centers for Disease Control and Prevention has involved over 100 experts in public health, prevention science and affected and infected communities to devise a five-year strategic
plan to cut the number of new HIV infections annually in the United States by half and address the global HIV epidemic. The plan’s four goals are:

1. Reduce the number of new HIV infections per year in the United States from an estimated 40,000 to 20,000 per year by 2005.

2. Through voluntary counseling and testing, increase the proportion of HIV-infected people in the United States who know they are infected from the current 70% to 95% by 2005.

3. Increase the proportion of HIV-infected people in the United States who are linked to appropriate care, prevention services and treatment services from the current estimated 50% to 80% by 2005.

4. Reduce HIV transmission and improve HIV/AIDS care and support through partnership with resource-constrained countries.

Research consistently shows the prevention benefit of early diagnosis and ongoing care and services for people living with HIV. In addition to leading longer and healthier lives, people who receive ongoing care for HIV disease and services to address other needs, such as substance abuse, lead safer lives – they are more likely to adopt and maintain safer sexual behaviors. Thus, early diagnosis and referral into prevention services, care and treatment have important prevention functions.

Research also clearly demonstrates the benefits of community-level HIV prevention programming to prevent those at risk for HIV from becoming infected. CDC’s mechanism for supporting communities in the identification of local HIV prevention priorities is called HIV prevention community planning. Community planning empowers local communities across the United States to use epidemiologic and surveillance data, behavioral science and other scientific information to make informed decisions about where and how to target resources, and is an integral part of CDC’s five-year strategic plan.

Scientists at the international AIDS conference in Durban, South Africa, estimated that providing access to community-level HIV prevention or small-group interventions to all those at risk for sexual transmission of HIV in the United States would cost upwards of $1 billion annually. Providing prevention services to all those at risk from injection drug-related HIV infection in the U.S. would cost an estimated $423 million annually.

Researchers estimate that the discounted cost of lifetime treatment for a person with HIV now averages about $155,000. With 40,000 people infected yearly, America faces an additional annualized cost of more than $6 billion each and every year. Clearly, prevention pays.

This five-year strategic plan for HIV prevention is visionary and ambitious, but it can be realized, with sufficient resources, political commitment and enhanced collaboration across all sectors (federal, state and local; public, private and non-profit). Level prevention funding will not equate to a stable HIV epidemic. Instead, as more and more people live longer with disease and have the opportunity to infect others, level funding could actually translate into increases in HIV infection and AIDS.
Selected Objectives and Strategies

The framework for the five-year strategic plan is **goals**, which are achieved through the fulfillment of **objectives**, which are in turn realized through **strategies**.

**Goal 1: Reduce new HIV infections per year in the United States from an estimated 40,000 to 20,000 per year by 2005.**

<table>
<thead>
<tr>
<th>Priority Objectives</th>
<th>Selected Strategies</th>
</tr>
</thead>
</table>
| Among people living with HIV, increase the proportion who consistently engage in behaviors that reduce risk of HIV transmission or acquisition. | 1. Develop and implement community and structural interventions to reduce stigma and discrimination surrounding HIV infection.  
2. Develop, implement and evaluate voluntary, peer-based HIV prevention interventions. |
| Among men who have sex with men, increase the proportion who consistently engage in behaviors that reduce risk of HIV transmission or acquisition. | 1. Develop, implement and evaluate evidence-based HIV prevention programs for gay men, particularly MSM of color and young MSM.  
2. Work with NGOs, the private sector and others to address the negative effects on prevention of stigma and discrimination associated with sexual orientation. |
| Among adolescents, increase the proportion who abstain from sexual intercourse or use condoms consistently and correctly if sexually active. | 1. Develop, implement and evaluate evidence-based, community-based HIV prevention programs that help adolescents delay intercourse and help them develop safer sexual practices, particularly for adolescents in high-risk situations, especially out-of-school youth, gay/lesbian/bisexual/transgender and questioning youth, youth in detention, runaway youth and youth of color.  
2. Develop, implement and evaluate evidence-based comprehensive school-based HIV prevention programs that help adolescents delay intercourse and help them develop safer sexual practices, particularly for youth of color.  
3. Coordinate/collaborate with SAMHSA, NIH and other partners to increase the research on effective programs that help adolescents prevent abuse of alcohol and other drugs.  
4. Develop, implement and evaluate evidence-based programs for positive family communication around sexual behavior. |
| Among injection drug users (IDUs), increase the proportion who abstain from drug use or who use harm reduction strategies to reduce risk of HIV transmission or acquisition. | 1. Collaborate with SAMHSA, NIH and other partners to develop, disseminate, implement and evaluate health education/risk reduction and harm reduction programs and counseling and testing programs targeting IDUs.  
2. Work with other federal, state and local partners to increase comprehensive services to IDUs, including HIV/STD testing, drug treatment, methadone maintenance and harm reduction programs.  
3. Continue to disseminate scientific evidence that needle exchange programs are effective at reducing |
<table>
<thead>
<tr>
<th>Priority Objectives</th>
<th>Selected Strategies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increase the motivation of at-risk individuals to know their infection status and decrease real or perceived barriers to HIV testing.</td>
<td>1. Work with a broad array of partners to identify, develop, implement and evaluate strategies to address real and perceived barriers to testing, such as fears concerning stigmatization, criminalization, partner notification, violence, risk of deportation and confidentiality. 2. Study the effects of risk-denial on individual motivation to be tested and implement strategies to overcome this barrier.</td>
</tr>
<tr>
<td>Improve access to voluntary HIV counseling and testing (VCT) in high seroprevalence communities and populations at risk.</td>
<td>1. Increase access to anonymous and confidential testing. 2. Increase the proportion of people with conditions (STDs, TB and hepatitis C) and behaviors (unprotected sex, multiple partners) that indicate HIV risk who are offered VCT. 3. Evaluate the effectiveness of various types of partner notification programs.</td>
</tr>
<tr>
<td>Increase the number of providers who routinely offer VCT for HIV in health care settings, including antenatal settings, as well as other venues.</td>
<td>1. Conduct studies to determine the effects of different pre-test counseling and consent approaches on provider willingness and ability to offer VCT. 2. In collaboration with professional organizations, develop guidance on the healthcare settings and patient populations for which VCT should be the standard of care. 3. Develop and implement education and training initiatives for physicians, nurses and other health care workers.</td>
</tr>
</tbody>
</table>
| Increase the percentage of people who know their HIV results after testing. | 1. Support the use of rapid tests to provide same-day screening results.  
2. Evaluate and monitor grantees’ rates of client return for test results and work with grantees to increase return rates as needed.  
3. Determine the effect of patient incentives and other strategies on increasing return rates. |
Goal 3: Increase the proportion of HIV-infected people in the United States who are linked to appropriate care, prevention services and treatment services from an estimated 50% to 80% by 2005.

<table>
<thead>
<tr>
<th>Priority Objectives</th>
<th>Selected Strategies</th>
</tr>
</thead>
</table>
| Work with public health, the private medical sector HRSA and other partners to reduce the disparities in access to prevention and care services that are experienced by communities of color and by women. | 1. Collaborate with HRSA, NIH, the affected communities and other partners to develop and implement a comprehensive research agenda that identifies and addresses barriers to prevention services and access to care.  
2. Promote cultural and linguistic competence in CDC-funded programs. |
| Work with public health, the private medical sector and other partners (e.g., SAMHSA, HRSA) to increase the percentage of people diagnosed with HIV who are successfully linked to culturally competent, science-based behavioral prevention services. | 1. Assure that HIV-infected people tested in CDC-funded sites obtain a comprehensive prevention assessment and appropriate referral to prevention case management (PCM) within 3 months of learning their HIV status.  
2. Collaborate with HRSA to encourage the establishment and maintenance of behavioral prevention services in public HIV/AIDS outpatient clinics.  
3. Increase the capacity of health care providers to provide behavioral prevention counseling.  
4. Develop a system to monitor HIV-infected patients’ linkage to prevention services. |
| Work with public health, the private medical sector, HRSA and other partners to increase the percentage of people diagnosed with HIV who are successfully linked to care within 3 months of learning their HIV status or of being re-identified as being HIV-infected but out of care. | 1. Publish guidelines for best practices for linkage from post-test counseling to medical evaluation.  
2. Conduct research to determine why previously diagnosed but currently out-of-care people didn’t initially access or remain in medical care and develop interventions to enhance care utilization. |
Goal 4: Reduce HIV transmission and improve HIV/AIDS care and support through partnership with resource-constrained countries.

<table>
<thead>
<tr>
<th>Priority Objectives</th>
<th>Selected Strategies</th>
</tr>
</thead>
</table>
| Decrease sexually transmitted HIV infections.           | 1. Develop and evaluate behavioral interventions to reduce the risk of acquiring or transmitting HIV and other STDs, particularly for sex workers and their clients, displaced populations, in- and out-of-school youth, those in the workplace and for other locally relevant populations.  
2. Expand VCT for HIV.  
3. Investigate the most effective intervention methods to address the role of STDs in HIV transmission and acquisition and to improve STD treatment services. |
| Develop the capacity of partners in host countries for HIV prevention and care efforts. | 1. Work with partner country governments and communities to strengthen their capacity to plan, implement, evaluate and monitor HIV interventions.  
2. Work with communities in partner countries to decrease HIV stigma.  
3. Build partners’ capacity to develop, review and implement scientific and operational research protocols according to internationally accepted bioethical precepts. |
| Expand and strengthen HIV/STD/TB surveillance programs. | 1. Strengthen HIV sentinel surveillance programs to monitor epidemic trends.  
2. Strengthen the collection and use of behavioral data.  
3. Strengthen laboratory testing.  
4. Promote the use of surveillance data for public health decision-making. |
| Improve basic scientific knowledge of HIV and the safety and efficacy of new technologies. | 1. Evaluate the safety and efficacy of HIV vaccine candidates and vaginal microbicides.  
2. Conduct and apply HIV virologic research, focusing on the epidemiology, ecology and evolutionary biology of HIV infection.  
3. Conduct HIV vaccine and microbicide preparedness work, including the development of relevant cohorts.  
4. Evaluate and apply new laboratory tests for HIV. |
| Decrease HIV infections from mother to child.           | 1. Expand access to VCT services for antenatal women.  
2. Conduct research on improving biomedical and behavioral methods to interrupt mother-to-child transmission.  
3. Expand access to antiretroviral drugs for HIV-infected pregnant women and their newborns.  
4. Provide appropriate breastfeeding alternatives. |
| Increase access to improved HIV care and support. | 1. Strengthen VCT programs to make critical linkages to care and support.  
2. Work with communities to decrease HIV stigma.  
3. Expand and strengthen programs that prevent and treat TB and other opportunistic infections.  
4. Conduct and apply research on the clinical management of HIV.  
5. Conduct research on the psychological and social needs of people living with HIV/AIDS and people affected by HIV/AIDS. |
| Decrease parenterally transmitted HIV infections. | 1. Strengthen the capacity of countries to provide sufficient safe blood for transfusion.  
2. Conduct and apply research on behavioral change methodologies, including targeted harm reduction programs, to prevent IDU-related transmission.  
3. Strengthen the capacity of health care workers to prevent parenteral HIV infection to themselves and to their patients. |
Foreword

Over the last two decades, HIV/AIDS prevention science has advanced dramatically. Mother-to-child HIV transmission has been drastically reduced, accounting for an estimated 300 to 400 perinatal HIV infections annually in recent years, thanks to widespread adoption of routine, voluntary HIV counseling and testing for pregnant women and the availability of the drug AZT to interrupt transmission from the pregnant woman to her baby. And new hope for reducing the risk of infection among men who have sex with men, injection drug users and women has been realized through strong community-level interventions, multi-faceted behavioral prevention that addresses people’s ability to make healthy decisions and sustain protective behaviors.

Change has accelerated in the last 5 years, with the advent of new drug combinations to treat HIV infection, delaying the onset of AIDS and offering the hope of reducing further transmission, as infected people’s viral loads are diminished and their potential infectiousness possibly reduced. But the promise of treatment advances is not without pitfalls: Research shows that optimistic attitudes about treatment may be contributing to increased risk behavior among young MSM as well as among other groups at risk for HIV infection. And, without lifelong prevention support services to help them adopt and maintain healthy behaviors, the growing number of people living longer with HIV form a wellspring of potential infection. Behavioral science continues to shed light on the best ways to motivate people to adopt and maintain safer behaviors, reducing their risk of acquiring HIV if they are seronegative or of transmitting HIV if they are already infected.

The face of the epidemic is changing as well – in addition to the groups who have been at highest risk since the beginning of the epidemic, MSM and injection drug users, other populations are also at risk. As shown in Figure 1 below, more and more people of color, and especially women and successive waves of young people, are placing themselves in harm’s way. CDC estimates that approximately 40,000 people per year are infected with HIV, a number that has remained relatively stable – but unacceptably high – for much of the past decade. At this point in the epidemic, it is time for CDC to undertake a new strategic plan for HIV prevention.
CDC is the federal agency charged with preventing HIV infections and AIDS. But no one agency can do that alone. To accomplish that mission, and to meet other national goals for public health, such as those in Healthy People 2010, CDC works with partners such as other federal agencies including HRSA, HCFA, NIH, SAMHSA and FDA, state and local health and education departments, community-based organizations and private-sector firms, to conduct activities within three broad areas essential to achieving public health goals: recognition, intervention and evaluation. CDC’s recognition activities – surveillance and research – help to better define and understand the various local HIV/AIDS epidemics across the nation. Intervention activities – prevention program implementation and technical assistance – based on behavioral, laboratory and medical science, work to contain the spread of HIV and AIDS. Evaluation activities – both program evaluation and policy research and development – assess intervention effectiveness and refine prevention approaches.

To develop this five-year strategic plan, CDC involved more than 100 experts from inside and outside the government: experts in behavioral science, epidemiology, care and treatment and the other disciplines required to address the HIV epidemic, community-based HIV prevention providers, members of infected and affected groups. These experts examined a situation analysis of the current epidemic, as well as a response analysis of CDC’s current activities. They then divided into four workgroups, one for each of the three domestic goals and one for the international goal, to develop objectives and strategies to address each of the four goals. The goals, objectives and strategies begin on page 28. Background information on the strategic plan development process is in Appendix A, beginning on page 55.

**How Are People Becoming Infected?**

**Adult and Adolescent HIV Infections**
**By Known Risk^ Reported in 1999**

<table>
<thead>
<tr>
<th>Risk Category</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men who have sex with men (46%)</td>
<td>6,000</td>
</tr>
<tr>
<td>Heterosexual (30%)</td>
<td>5,000</td>
</tr>
<tr>
<td>Injecting drug use (18%)</td>
<td>4,000</td>
</tr>
<tr>
<td>MSM/IDU (5%)</td>
<td>3,000</td>
</tr>
<tr>
<td>Blood transfusion/components/tissue (&lt;1%)</td>
<td>2,000</td>
</tr>
<tr>
<td>Hemophilia/coagulation disorder (&lt;1%)</td>
<td>1,000</td>
</tr>
</tbody>
</table>

^Total reported N= 21,186. Graph excludes 8,726 whose risk was not identified at the time of report.

*From the 32 areas with confidential adult and adolescent HIV reporting.

In 1999, CDC received reports of 21,186 adult and adolescent HIV infections from 32 areas with adult and adolescent name-based HIV reporting (Fig. 2). The states reporting HIV infections did not include some of the areas hardest hit, such as California and New York – clearly, the numbers reported would rise considerably if all states and territories conducted HIV reporting.

The majority of cases reported in which the person’s risk was known – 46% – were among men who have sex with men. Heterosexuals, mostly women, represented the next largest category at 30%. Injecting drug use (IDU) accounted for 18% of the
reported cases classified by a specific risk. A significant percentage of cases were reported without a risk noted at the time of the initial report of HIV infection. NIR or “no risk reported or identified” cases are people whose cases are currently under investigation by local health departments; people who have died, declined to be interviewed or were lost to follow up; and people whose cases were investigated and no exposure could be identified. As NIR cases are investigated, people are reclassified into the proper exposure category if risk is determined.

Ever-Changing Epidemic

*The AIDS epidemic continues to evolve, making inroads in vulnerable populations.* People of color, especially women, and young people are increasingly at risk, joining the rolls of the two groups historically hardest hit: men who have sex with men and injecting drug users.

**People of color** are increasingly at risk, as shown in the pie charts below.

- In 1997, HIV prevalence was higher among African-Americans than among any other racial or ethnic group surveyed. As Figure 3 below shows, it is estimated that half the men becoming infected are African-American; and the majority (60%) are MSM.

- In 1999, more African-Americans were reported with AIDS than any other racial/ethnic group. Approximately two-thirds (63%) of all women reported with AIDS were African-American and 42% of all men. African-American children represented almost two-thirds of all reported pediatric AIDS cases. In addition to suffering disproportionately from AIDS, African American women are also disproportionately infected with HIV. As shown in Figure 3, it is estimated that African American women account for 64% of new HIV infections among women.

- In 1999, Hispanics represented 13% of the U.S. population, but accounted for 19% of the total number of new AIDS cases reported that year. Latinas represent 18% of estimated new HIV infections among women and Hispanic men, 20% of estimated new infections among men (Fig. 3).

![Estimates of New Infections Among Men and Women, By Race and Risk](image)
**Women.** In 1992, women accounted for 13.8% of people living with AIDS. By end-year 1998, the proportion had grown to 20%. Figure 4 shows women’s AIDS rates in 1998 by region and by race/ethnicity. AIDS case rates are highest in the Northeast, followed by the South. CDC estimates that between 120,000 and 160,000 adult and adolescent females are now living with HIV infection, including those with AIDS.

**Young people.** It is estimated that about half of all new HIV infections are among young people under age 25, and the majority are infected sexually. In 1999, 1,813 young people ages 13 to 24 were reported with AIDS. Although the overall number of new AIDS diagnoses is declining, due to prevention and to highly effective drug treatment, a CDC analysis of HIV cases diagnosed in 25 states reporting HIV infections from 1994 to 1997 found no comparable decline in newly diagnosed HIV infections among youth. Figures 5 and 6 show AIDS cases reported through December 1999 by gender and age group.
**Men Who Have Sex With Men.** Gay and bisexual men of all races remain at alarming risk for HIV infection. In fact, risk may again be increasing in some communities, as evidenced by recent outbreaks of sexually transmitted diseases, particularly gonorrhea and syphilis, among MSM. Prevention issues include burn-out among older MSM, mistaken beliefs that HIV is no longer a serious disease, a new generation of young gay and bisexual men who must be reached and the unique cultural issues MSM of color face regarding both their race/ethnicity as well as their sexual orientation. A study of 1,942 HIV-infected gay and bisexual men in 12 U.S. cities found that a growing percentage reported engaging in unprotected anal sex. The proportion of gay and bisexual men who had unprotected anal sex during the previous 12 months rose from 13% in 1995-1996 to 19% in 1997-1998 – an increase of nearly 50%. HIV-infected MSM who had unprotected anal sex were more likely to have multiple partners, use injection drugs or crack cocaine and have less than 12 years of education.

**IDUs** (injecting drug users), their partners and their children account for 36% of all AIDS cases reported in the U.S. through 1999. They continue to be at risk for HIV infection, accounting for 16% of the cumulative HIV infections reported from areas with confidential HIV infection surveillance.

**Successful Prevention Works At Multiple Levels**

In an era of highly effective drug therapies, more people are living with HIV infection, as shown in the chart below (Fig. 7). CDC estimates that between 800,000 and 900,000 people were living with HIV in the U.S. at the end of 1998. But optimism about treatment successes has led some people – both infected and uninfected – to become complacent about HIV prevention. Behavioral studies have shown that some people believe treatment advances make it less important to practice safer behaviors. As people live longer with infection, absent targeted behavioral interventions, they have the potential to spread infection. And, although HAART may reduce
people’s infectiousness, and thus their ability to transmit the virus to others, it is no substitute for primary prevention. HAART isn’t suitable or effective for everyone. In the U.S. and around the world, people die everyday from AIDS, even those who had HAART.

People living with HIV need comprehensive care, including prevention case management services to prevent infecting others and to prevent complications of HIV infection. But estimates are that up to one-third of those living with HIV in America are unaware they are infected with HIV. The first step in securing needed prevention, care and treatment services is being tested for HIV and learning one’s serostatus. Behavioral studies have demonstrated that, after learning they are infected, many people change their behavior, to avoid infecting others. Thus, learning one’s status is, in itself, an important element of prevention. Continued prevention efforts are critical, emphasizing that there is no cure for HIV disease.

Successful prevention efforts avert HIV infection. The most successful prevention works at multiple levels simultaneously – at individual, social network and community levels, as well as at the structural level, addressing the sometimes hidden societal barriers to effective prevention.

The objectives and strategies that follow are designed to optimize the benefits of a continuum of HIV prevention and treatment, as reflected in the goals of the strategic plan. In this continuum:

Individuals determine their HIV status through voluntary counseling and testing as early as possible after their exposure to HIV.

If they test negative for HIV, they use the full array of existing prevention interventions and services to adopt and maintain HIV risk reduction [Goal 1].

If they test positive for HIV, they use quality prevention services and work to adopt and sustain lifelong protective behaviors to avoid transmitting the virus to others [Goals 2 and 3].

If they are HIV-infected, they enter the care system as soon as possible to reap the benefits of primary care and treatment [Goal 3].

Once in the care system, they benefit from comprehensive quality services, including mental health and substance abuse services, treatment for HIV infection, opportunistic infections and other infections, such as STDs and tuberculosis [Goal 3].

In conjunction with their providers and support networks, they work to develop strategies to optimize adherence to their prescribed therapies [Goal 3].
**HIV Prevention Works**

America’s HIV prevention investments have paid off. Prevention has helped slow the rate of new HIV infections in the United States from over 150,000 in the mid 1980s to around 40,000 per year now – a remarkable decline, but new infections are still unacceptably high. AIDS remains a crisis in the U.S.

There are prevention tools that we know work. As detailed in CDC’s *Compendium of HIV Prevention Interventions with Evidence of Effectiveness*, HIV prevention programs have been effective with a variety of populations: clinic patients, heterosexual men and women, youth at high risk, incarcerated populations, injection drug users and MSM. Interventions have been delivered to individuals, groups and communities, in settings ranging from storefronts to gay bars to health centers to public housing to schools.

For example, effective prevention among men who have sex with men, injection drug users and pregnant women helped ensure that –

- HIV seroprevalence among white MSM in the U.S. declined by 50% between 1988 and 1993.
- HIV seroprevalence among injection drug users in New York City dropped more than 40% during the 1990s.
- The estimated number of U.S. infants who acquired AIDS from mother-to-child transmission declined 75% from 1992 to 1998.

**HIV Prevention Pays**

HIV prevention pays. Researchers estimate that the cost of lifetime treatment for a person with HIV now averages about $155,000. Estimates are that 40,000 people are infected yearly, resulting in an annualized cost of more than $6 billion each and every year. The cumulative cost of lifetime treatment doubles yearly if the number of infections stays steady, as it has over the last decade. In the last 5 years alone, an estimated 200,000 people have been infected with HIV. Treating them over the rest of their lives will cost the nation $31 billion, not counting inflation or further treatment advances that might add to costs.

At CDC’s current budget level, only 4,000 infections must be prevented annually to actually result in cost savings, and only 1,300 must be prevented for the investment to be cost
effective. Most researchers agree that the number of infections actually prevented every year far exceeds the cost-savings level.

Further reductions in the number of people infected annually – and the concomitant reductions in human suffering – will be proportionate to funds invested. Our nation cannot reduce HIV infections further without additional investment.

CDC’s Domestic HIV Prevention Budget: $637 M
FY 99 Allocations

Federal HIV/AIDS Spending: FY 99

CDC’s fiscal year 1999 (or FY 99) domestic budget for HIV prevention was $637 million, allocated along the proportions shown in the pie chart at left (Fig. 8).

To accomplish the four goals specified in this draft strategic plan, the nation will need to devote additional resources to HIV/AIDS prevention. Reducing new domestic infections by half will require substantial new resources over the agency’s current base funding. The proportion of prevention dollars in federal HIV/AIDS spending, 8% of all monies allocated to HIV/AIDS in fiscal year 1999, is shown in Figure 9.

HIV Prevention Must Be Accountable

CDC’s guiding principles in the strategic planning process are the same as they are for all our prevention programs:

- **Effectiveness** – CDC will evaluate its programs for effectiveness and require grantees to do the same, in order to ensure that our programs do the utmost to prevent HIV, given the resources provided to us.

- **Accountability** – CDC pledges to be accountable to the American people for conducting sound HIV/AIDS prevention activities.

- **Transparency** – CDC intends for its activities and funding to be clear to those outside the agency.

- **Science-Based Activities** – CDC’s efforts will be based on the best science currently available.

- **Collaboration and Partnerships** – CDC will conduct HIV/AIDS prevention in conjunction with partners at all levels – federal, state and local – in the public sector, private sector and not-for-profit sector to address multiple local epidemics in the most efficient way possible.

- **Comprehensiveness** – CDC will continue its multifaceted approach to HIV prevention that includes strategies to address individual, community, societal and structural level prevention needs.
CDC’s Goals for HIV Prevention

1. Reduce the number of new HIV infections per year in the United States from an estimated 40,000 to 20,000 per year by 2005.

2. Through voluntary counseling and testing, increase the proportion of HIV-infected people in the United States who know they are infected from the current 70% to 95% by 2005.

3. Increase the proportion of HIV-infected people in the United States who are linked to appropriate care, prevention services and treatment services from the current estimated 50% to 80% by 2005.

4. Reduce HIV transmission and improve HIV/AIDS care and support through partnership with resource-constrained countries.
Overarching Issues

As the four expert workgroups drafted and refined their recommendations to CDC, it became apparent that a number of issues crosscut all the goals, affecting HIV prevention at all levels. These issues are, in many instances, beyond the traditional purview of public health. For HIV/AIDS prevention to succeed, they must be addressed by a broad coalition of prevention partners, including public health, other social services agencies, faith communities, economic development agencies, health care purchasers, the justice system, the private sector and the so-called third sector, or not-for-profits and foundations, many of which are active and capable players in the HIV/AIDS arena.

Many of the issues that follow will be addressed in the action steps that will spell out implementation of this strategic plan. CDC will be developing the action steps following the public comment period on the plan. Among the most pressing cross-cutting issues are these:

Stigma associated with HIV/AIDS continues to profoundly affect prevention efforts, leading people to deny risk … avoid testing … delay treatment … and suffer needlessly. While stigma’s pernicious effects are perhaps most obvious in countries other than the U.S., where people may be shunned and physically menaced, stigma negatively affects Americans as well. It is found at the structural level, in the form of laws and regulations, as well as more explicitly at community and individual levels. Homophobia continues to hamper prevention efforts at all levels – from the individual at risk or infected, who may deny his risk because of internal conflicts – to the broader culture, which delivers anti-gay messages, institutionalizes homophobia through structural mechanisms such as laws that regulate intimate sexual behavior and lags in its support of sensitive and honest prevention for gay and bisexual youth, young adults and older men. Stigma associated with addiction and illicit drug use also results in laws and other restrictions on effective prevention. Likewise, persistent social and institutional racism and gender and economic inequities stifle effective HIV prevention. Planning workgroups agreed with CDC that, for each of these groups at risk, stigma, stereotyping and prejudice must be addressed for prevention to be most effective. Political leadership and will are necessary to address these underlying issues, so critical to prevention’s success.

At home and abroad, HIV continues to stalk our most vulnerable populations, people who are marginalized because of race or ethnicity, sexual orientation, age or gender. For HIV/AIDS prevention to succeed, the special needs of those populations must be sensitively addressed, by culturally competent programs and staff. Cultural competence must be demonstrated not only by intervention programs and staff, but also by surveillance staff, researchers (and their investigations), as well as by those delivering prevention services, care and treatment programs to those who are HIV-infected.

In addition to cultural competence, CDC must assure that the programs it funds are of documented prevention effectiveness. Before holding grantees to this standard, however, the agency must work to ensure that training and technical assistance are available to help grantees succeed in delivering interventions of the highest possible quality. A key component of any quality improvement program will be evaluation – which requires not only training and technical assistance, but also adequate funding – to assess the effectiveness of prevention programming in order to make adjustments as necessary to ensure high quality.

Finally, to succeed, this plan requires a number of structural supports, including:
- Better collaboration between and among the various federal agencies with responsibilities for HIV/AIDS, substance abuse and STD prevention, research, care and treatment, including NIH, HCFA, HRSA, SAMHSA and FDA, as well as among
The plan demands continuity of care for persons who are HIV-infected, moving seamlessly from testing and counseling to referral to care and treatment for HIV disease as well as other individual needs, such as STD treatment, drug treatment and ongoing prevention services. Absent strong linkages between and among programs, this plan cannot succeed.

- **Capacity-building** at all levels. No one knows more about a community than that community itself. CDC has always believed that, with the right kind of scientific support and technical assistance, communities are best able to identify their epidemics and how to fight them. Workgroups noted that surveillance information must be refined to give a better local picture and, beyond that, community planning groups, grantees and others will need a more extensive program designed to build local capacity to best address HIV/AIDS prevention needs.

- **Better measurement.** The workgroups noted that measurement activities will have to be increased to provide baseline data and ongoing evaluation of progress in meeting goals, objectives, strategies and action steps. In many instances, workgroups were frustrated that data were not available so that explicitly measurable objectives and strategies could be created.

- **Additional funding,** to address currently unmet gaps and needs. As noted earlier, at CDC’s current funding, the goals of this plan cannot be accomplished.

## How Will The Plan Be Used?

Following the comment period on this draft plan, which runs from September 11, 2000, to October 23, 2000, CDC anticipates finalizing the strategic plan during the remainder of calendar year 2000. Concomitant with the public comment period on goals, objectives and strategies, action steps will be developed to direct agency efforts in accomplishing high priority strategies and objectives. The agency will also address the issue of relative prioritization. That is, CDC must determine whether each of the four goals is of equal priority. Additionally, the agency must address the question of prioritization within goals and determine how funding is best allocated among the priorities as the workgroups have defined them.

**Upon completion, the plan will be used to:**

- assess current budget allocations against the priorities in the plan and to realign spending as needed;
- define unmet needs;
- allocate new resources, if they become available;
- direct prevention research;
- highlight opportunities to strengthen collaboration across federal agencies and with other partners to enhance prevention;
- assess the annual performance of CDC and its grantees in meeting priority goals, objectives and strategies;
- serve as the basis of a yearly “report card” to the public on the activities of CDC and its grantees.
Elements of Successful HIV Prevention

To succeed, HIV prevention must be comprehensive. These elements are required for HIV prevention to work:

- A community planning process
- Epidemiologic and behavioral surveillance; compilation of other health and demographic data relevant to HIV risks, incidence or prevalence
- HIV counseling, testing and referral and partner counseling and referral, with strong linkages to medical care, treatment and needed prevention services.
- Health education and risk reduction (HE/RR) activities, including individual-, group- and community-level interventions
- Accessible diagnosis and treatment of other STDs
- Public information and education programs
- Comprehensive school health programs
- Training and quality assurance
- HIV prevention capacity-building activities
- An HIV prevention technical assistance assessment and plan
- Evaluation of major program activities, interventions and services

The following goals, objectives and strategies address each of these essential components of a comprehensive HIV prevention program.
Goal 1

Reduce the number of new HIV infections per year in the United States from an estimated 40,000 to 20,000 per year by the year 2005.

Objectives: Rank-Ordered Priority – Objectives are ranked from high (1) to lower (12) priority. Even lower priority objectives are considered important elements of comprehensive HIV prevention, and will not be eliminated from the array of CDC-sponsored activities. However, lower priority objectives may not receive supplementary or new resources.

1. Among people living with HIV, increase the proportion who consistently engage in behaviors that reduce risk of HIV transmission or acquisition.

2. Among men who have sex with men (MSM), increase the proportion who consistently engage in behaviors that reduce risk of HIV transmission or acquisition.

3. Among adolescents, increase the proportion who abstain from sexual intercourse or who use condoms consistently and correctly if sexually active.

4. Among injection drug users (IDUs), increase the proportion who abstain from drug use or who use harm reduction strategies to reduce risk of HIV transmission or acquisition.

5. Among at-risk sexually active women (including women who have sex with women), and at risk heterosexual men, increase the proportion who consistently engage in behaviors that reduce risk of HIV transmission or acquisition.

6. Increase the proportion of people living with HIV and at highest risk for HIV who are tested for STDs and treated appropriately.

7. Increase the number of interventions of documented effectiveness and the proportion of providers funded by CDC that successfully provide demonstrably effective HIV prevention interventions.

8. Support realistic and feasible evaluation efforts to ensure the delivery of interventions of the highest possible quality.

9. Develop a monitoring system to estimate the number of new infections occurring each year in the U.S. and to provide locally relevant data for community planning.

10. Reduce perinatal transmission.

11. Reduce occupational HIV transmission.

12. Maintain safety of the blood supply.
Rationale

Decreasing new infections by half is an ambitious goal – but it can be accomplished with sufficient resources to deploy interventions of proven effectiveness.

To achieve this goal, resources must be directed to those most at risk, as demonstrated by sound epidemiologic and surveillance information. Men who have sex with men, injecting drug users and communities of color, particularly young women, must receive targeted, sustained, culturally appropriate prevention programming to break the cycle of HIV infection in America. Prevention must address the barriers to protective behaviors – barriers that are located within the individual, in the community and within the broader social context. For example, women may feel powerless to insist on condom use with partners, even though they know their partners are not monogamous. Communities may not insist on comprehensive HIV prevention programs in schools, even in the face of teen pregnancies and STDs, sure indicators that young people are also at risk for HIV infection. Our broader society may continue to condone discriminatory legislation, such as laws that criminalize certain sexual behaviors and make prevention a harder sell.

In order to cut new infections in half, all the factors that affect an individual’s ability to make healthy choices must be addressed. Communities must be better equipped with local data to know who’s at risk; they must have an array of effective interventions available and the capacity to implement and evaluate them at the local level; and they must be able not only to deter risky behavior but promote healthy behavior, through a variety of individual and group interventions, community-level supports and structural level changes.

The goal of cutting new infections in half will not be achieved without accomplishing the other two domestic goals. Ensuring that all those infected with HIV are aware of their status, in order to receive the benefits of improved HIV therapies as well as the benefits of counseling and support they need to reduce the risk of infecting others, is vital, as described in goal 2 beginning on page 36. Additionally, HIV prevention must be integrated with other services, such as STD and TB screening and treatment, reproductive health services, mental health services and drug use prevention and treatment, as described in goal 3, beginning on page 41. Those at risk for or living with HIV infection are often also at risk for other health problems. Integrating services, making it easier for people to seek and receive care and prevention interventions, will increase effectiveness as well as efficiency.

Clearly, CDC must work with a broad array of partners – other federal agencies such as HRSA, HCFA, NIH and SAMHSA; state and local health and education departments; community-based organizations; faith groups; and the private sector, including health care providers, the media, large purchasers of health insurance and others – to achieve the goals of this strategic plan.
Objectives and Strategies – Objectives are ranked from high (1) to lower (12) priority. Even lower priority objectives are considered important elements of comprehensive HIV prevention, and will not be eliminated from the array of CDC-sponsored activities. However, lower priority objectives may not receive supplementary or new resources. Strategies are rank-ordered in terms of their priority.

Objective 1: Among people living with HIV, increase the proportion who consistently engage in behaviors that reduce risk of HIV transmission or acquisition.

Strategies:
1. Develop and implement community and structural interventions to reduce stigma and discrimination surrounding HIV infection.
2. Develop, implement and evaluate voluntary, peer-based HIV prevention interventions (individual, couples, groups, community, social marketing and structural level interventions) that address the diversity of individuals and populations living with HIV and their partners.
3. Conduct research to determine the most effective ways to involve HIV-infected persons as peer educators and counselors, and to involve them in the design and development of prevention strategies.
4. Support partner counseling and referral services to assure that partners potentially exposed to HIV receive testing and counseling and appropriate early evaluation and care.

Objective 2: Among men who have sex with men (MSM), increase the proportion who consistently engage in behaviors that reduce risk of HIV transmission or acquisition.

Strategies:
1. Develop, implement and evaluate evidence-based HIV prevention programs for gay men, particularly MSM of color and young MSM, as indicated by local epidemiologic data.
2. Work with non-governmental organizations, the private sector and others to address the negative effects on prevention of stigma and discrimination associated with sexual orientation.
3. Based on local epidemiologic data, develop, implement and evaluate evidence-based HIV prevention programs for persons at increased risk for HIV who use alcohol and other drugs.
Objective 3: Among adolescents, increase the proportion who abstain from sexual intercourse or use condoms consistently and correctly if sexually active.

Strategies:
1. Develop, implement and evaluate evidence-based, community-based HIV prevention programs that help adolescents delay intercourse and help them develop safer sexual practices, particularly for adolescents in high-risk situations, especially out-of-school youth, gay/lesbian/bisexual/transgender and questioning youth, youth in detention, runaway youth and youth of color.
2. Develop, implement and evaluate evidence-based comprehensive school-based HIV prevention programs that help adolescents delay intercourse and help them develop safer sexual practices, particularly for youth of color.
3. Coordinate/collaborate with SAMHSA, NIH and other partners to increase the research on effective programs that help adolescents prevent abuse of alcohol and other drugs and increase the awareness of the connection between drug use and sexual risk-taking.
4. Develop, implement and evaluate evidence-based programs for positive family communication around sexual behavior.

Objective 4: Among injecting drug users (IDUs), increase the proportion who abstain from drug use or who use harm reduction strategies to reduce risk of HIV transmission or acquisition.

Strategies:
1. Collaborate with SAMHSA, NIH and other partners to develop, disseminate, implement and evaluate health education/risk reduction (HE/RR) and harm reduction programs and voluntary HIV counseling and testing (VCT) programs targeting IDUs.
2. Work with other federal, state and local partners to increase comprehensive services for IDUs, including HIV/STD testing, drug treatment, methadone maintenance and harm reduction programs to promote non-sharing of injection equipment and use of sterile injection equipment.
3. Work with federal partners, corrections institutions, health departments and CBOs to provide incarcerated individuals with HE/RR and linkages to HIV and substance abuse prevention programs, mental health programs and other community-based services.
4. Continue to disseminate the scientific evidence that needle exchange programs are effective in reducing HIV infection while not increasing drug use.
5. In localities where needle exchange programs exist, encourage CDC grantees (who may interact with the same population using the exchange) to provide comprehensive HIV/STD education, VCT and referral to drug and mental health centers.
6. Collaborate with other federal agencies to develop, implement and evaluate prevention strategies that address non-injection drug use (e.g., crack cocaine, crystal methamphetamine) as a co-factor for HIV transmission.
Objective 5: Among at-risk sexually active women (including women who have sex with other women), and at-risk heterosexual men, increase the proportion who consistently engage in behaviors that reduce risk of HIV transmission or acquisition.

Strategies:
1. Develop, implement and evaluate evidence-based HIV prevention programs that strengthen the capacity of women, especially women of color, to make decisions to reduce their sexual risk and increase their protective behaviors (e.g., correct, consistent and appropriate condom use, reductions in higher risk sexual practices with multiple partners).
2. Collaborate with NIH, FDA, private industry and other partners to increase the availability and acceptability of female-controlled HIV/STD prevention technology (e.g., microbicides and female condom).
3. Increase the research on the effectiveness of providing HIV prevention interventions in STD clinics, primary care and family planning settings, especially in communities of color.
4. Increase consistent and correct condom use by men, especially in communities of color.
5. Based on local epidemiologic data, develop, implement and evaluate evidence-based HIV prevention programs for persons at increased risk for HIV who use alcohol and other drugs.

Objective 6: Increase the proportion of people living with HIV and at highest risk for HIV who are tested for STDs and treated appropriately.

Strategies:
1. Increase awareness of HIV prevention providers of how STDs impact health and increase risk of HIV transmission and how to appropriately test and care for patients with STDs.
2. Increase the percentage of primary care providers for people at risk for HIV and living with HIV who perform routine and periodic testing for STDs.
3. Increase awareness among people living with HIV and people at increased risk for HIV of how STDs impact health and increase risk of HIV transmission.
4. Increase access to STD clinical care for people at increased risk for HIV and STDs by expanding service delivery venues to community-based organizations and non-traditional venues.
5. Increase the number of public HIV counseling and testing sites offering voluntary STD screening.
Objective 7: Increase the number of interventions of documented effectiveness and the proportion of prevention providers funded by CDC that successfully provide demonstrably effective HIV prevention interventions.

Strategies:
1. Promote a collaborative partnership model of intervention research, development and dissemination among prevention providers, affected populations, federal partners (e.g., NIH and SAMHSA), health departments, community planning groups, education departments and researchers to develop and test best interventions.
2. Fund evaluations of field-based intervention programs with strong reputations to identify additional effective interventions.
3. Conduct field efficacy trials of research-proven interventions implemented by non-researcher prevention programs.
4. Identify and address gaps and deficiencies in HIV prevention science, especially for target populations with fewer interventions of documented effectiveness, such as MSM of color and transgender persons.
5. Develop and support multiple mechanisms for identifying, evaluating and communicating best practices from the field (i.e., non-research, service provision settings) to community planning groups, directly funded CBOs and other prevention partners.
6. Fund intervention research projects with CBOs and health departments and require them to have a plan to sustain the interventions after the research projects end, whenever researched interventions are shown to be effective.
7. Institute evaluation and feedback to CDC on its technology transfer/diffusion, technical assistance and capacity-building initiatives.
8. Establish a mechanism(s) for ongoing dialogue and communication between CDC, CBOs, federal partners, health departments, community planning groups and researchers about technology transfer/diffusion.

Objective 8: Support realistic and feasible evaluation efforts to ensure the delivery of interventions of the highest possible quality.

Strategies:
1. Work with other federal partners funding HIV prevention (for example, SAMHSA) to standardize process and outcome evaluation protocols and institute minimum standard process evaluation measures consistent with evaluation requirements of other federal partners funding HIV prevention.
2. Fund rigorous process, outcome and impact evaluation for HIV prevention programs and provide technical assistance to facilitate adoption.
Objective 9: Develop a monitoring system to estimate the number of new infections occurring each year in the U.S. and to provide locally relevant data for community planning.

Strategies:
1. Explore the feasibility, and if feasible, develop a sampling frame to assess prevalent and incident HIV cases in sentinel sites or communities across the country; use modeling techniques to project an estimate of the new HIV infections occurring each year in the U.S.
2. Use new technology to assess incident cases as part of the monitoring effort and as part of state-based HIV case surveillance.
3. Develop, implement and evaluate measures of the prevalence of behavioral risk to help quantify the behavioral objectives presented in this plan.
4. Develop guidelines and provide support for systems to assist state and local health departments and education departments to better assess risk factors and the social context of new HIV infections and to communicate these findings in useful ways to planning groups and CBOs.
5. Provide technical assistance and resources to state and local health departments that wish to establish monitoring strategies similar to the national monitoring system.

Objective 10: Reduce perinatal transmission.

Strategies:
1. Work with other federal partners and private health care providers to routinize voluntary HIV counseling and testing, with informed consent, for all pregnant women, including those with no prenatal care.
2. Work with the array of professional organizations (e.g., physicians, midwives and nurses associations), medical, midwifery and nursing schools, the private medical sector (e.g., managed care organizations) and other federal partners to increase HIV-infected women’s and HIV-exposed infants’ early access to appropriate prevention (including elective cesarean section) and treatment.
3. Ensure that all jurisdictions have the necessary surveillance data on HIV in childbearing-aged women, pregnant women and perinatally exposed children to plan, target and evaluate programs to reduce perinatal transmission.
4. Work with federal partners, state and local health departments and providers to increase utilization of early and comprehensive prenatal care for all pregnant women, regardless of income, insurance or ability to pay.
5. Work with other partners to research the barriers to the use of AZT for perinatal HIV prevention by women at high risk.
6. Work with other partners to assess the effects of rapid screening on testing rates among women with no prenatal care in labor.
7. Work with other partners to assess the effectiveness of ultra-short antiretroviral regimens for pregnant women who do not obtain care until labor and delivery.
Objective 11: Reduce occupational transmission of HIV.

Strategies:

1. Encourage the availability and use of effective engineering controls (e.g., engineered sharps injury prevention devices) and personal protective equipment (e.g., gloves) and their use by health care workers.
2. Advocate for interventions in health care facilities (e.g., engineering controls, personal protective equipment, work practices, work organization and health communication strategies) that are effective in reducing exposure to blood and body fluids among health care workers.
3. Implement surveillance systems to track the distribution and determinants of bloodborne exposures (including the surveillance of effective interventions) and their trends over time among health care and other exposed workers in all settings.
4. Encourage the use of work practices that reduce exposures to blood and body fluids by health care workers and the modification of work organization factors (e.g. staffing and management commitment to safety) that impact exposures to blood in health care facilities.
5. Encourage the use of health communication strategies that convey effective techniques for reducing exposure to blood and body fluids among health care workers.
6. Work with employers and insurers to provide information about post-exposure prophylaxis and the importance of seeking appropriate and timely post-exposure treatment to health care workers (including emergency response workers).

Objective 12: Maintain safety of the blood supply.

Strategy:

1. Continue to monitor and preserve the safety of the blood supply.
GOAL 2

Through voluntary counseling and testing, increase the proportion of HIV-infected people in the United States who know they are infected from the current 70% to 95% by 2005.

Objectives: Rank-Ordered Priority – Objectives are ranked from high (1) to lower (4) priority. Even lower priority objectives are considered important elements of comprehensive HIV prevention, and will not be eliminated from the array of CDC-sponsored activities. However, lower priority objectives may not receive supplementary or new resources.

1. Increase the motivation of individuals to know their infection status and decrease real and perceived barriers to HIV testing.

2. Improve access to voluntary HIV counseling and testing (VCT) in high seroprevalence communities and populations at risk.

3. Increase the number of providers who routinely offer VCT for HIV in health care settings, including antenatal settings, as well as other venues.

4. Increase the percentage of people who know their results after HIV testing.
**Rationale**

In order for HIV-infected people to receive the benefits of improved HIV therapies and prophylaxis for opportunistic infections, as well as of the benefits of counseling to reduce the risk of infecting others, these individuals need to know their infection status. While all at-risk sexually active people should be encouraged to be counseled and tested for HIV, prevention resources for counseling and testing must be targeted to those whose behaviors place them at increased risk for infection. Strategies for those who deny their risk, those who recognize their risk but have not been tested and those who underestimate or are unaware of their risk will all be different. Targeted approaches for each group are essential. Special emphasis should be placed on youth at high risk to learn their status early – and when HIV negative, to maintain that status through prevention.

To achieve the goal of increasing the proportion of HIV-infected Americans who learn their serostatus through high-quality, client-centered voluntary counseling and testing,* several crosscutting strategies must be implemented or maintained:

- To maximize the acceptance and delivery of testing services in at-risk communities, HIV counseling and testing must be done in ways that address the cultural variations of our nation’s diverse communities.

- CDC programs designed to increase knowledge of HIV infection status must be developed in collaboration with national, state and local partners (both government and non-governmental organizations) and with input from community leaders.

- New rapid testing technologies should be evaluated to enable testing in nontraditional settings, such as street outreach programs, and to provide screening test results during initial patient encounters.

- Partner notification services to identify at-risk people who should be offered testing should be increased.

- All public health jurisdictions should ensure the availability of anonymous HIV testing.

---

*Note: As described in CDC’s guidelines for counseling and testing (including laboratory guidelines).*
Objectives and Strategies – Objectives are ranked from high (1) to lower (4) priority. Even lower priority objectives are considered important elements of comprehensive HIV prevention, and will not be eliminated from the array of CDC-sponsored activities. However, lower priority objectives may not receive supplementary or new resources. Strategies are rank-ordered in terms of their priority.

Objective 1: Increase the motivation of at-risk individuals to know their infection status and decrease real and perceived barriers to HIV testing.

Strategies:
1. Work with a broad array of partners to identify, develop, implement and evaluate strategies to address real and perceived barriers to testing – such as fears concerning stigmatization, criminalization, partner notification, violence, risk of deportation and confidentiality (including the impact of implementing HIV named reporting) – at an individual, community, societal and structural level.
2. Study the effects of risk-denial on individual motivation to be tested and implement strategies to overcome this barrier.
3. Develop and implement effective marketing strategies to promote testing in at-risk groups, including enhancing the at-risk public’s knowledge of primary infection indicators.
4. Use mass media outlets and community-based communications networks to disseminate news information related to testing matters quickly (generally within 24 hours of an event).
5. Support the development and application of new models of voluntary HIV counseling and testing, including couples testing, group-based approaches and alternative methods of providing results.
6. Support the use of tests that do not require needles (e.g., tests of saliva and urine).
7. Increase patient-level interventions to encourage those at-risk for HIV infection to request testing, such as tear-off or check-off slips to request a test.

Objective 2: Improve access to voluntary counseling and testing (VCT) in high seroprevalence communities and populations at risk.

Strategies:
1. Increase access to anonymous and confidential testing.
2. Increase the proportion of persons with conditions (e.g., tuberculosis, sexually transmitted diseases and hepatitis C) and/or behaviors (such as unprotected sex and multiple partners, substance abuse) that indicate HIV risk who are offered VCT.
3. Evaluate the effectiveness of various types of partner notification programs in order to increase the proportion of at-risk sexual or needle-sharing partners who are notified of their risk; receive counseling and voluntary testing; return for their test results; and, if
infected, are referred to follow-up or, if negative, receive prevention services to reduce their risk.

4. Increase the availability of free or low-cost testing at both clinical and non-clinical sites, such as community-based organizations, street outreach programs, faith-based service centers and family planning clinics in high seroprevalence areas.

5. Support public health agencies to assist state and local correctional facilities, including juvenile detention facilities, as well as probation and parole systems, to provide HIV educational services and VCT.

6. Increase the numbers of sexually active youth and young adults who are routinely offered VCT.

7. Increase the number of providers who routinely offer VCT to all pregnant women.

Objective 3: Increase the number of providers who routinely offer VCT for HIV in health care settings, including antenatal settings, as well as other venues.

Strategies:

1. Conduct studies to determine the effects of different pre-test counseling and consent approaches on provider willingness and ability to offer routine VCT.

2. In collaboration with professional organizations, develop guidance on the healthcare settings and patient populations for which VCT should be considered a standard of care.

3. Develop and implement education and training initiatives for physicians, nurses and other health care providers to promote and enhance quality of VCT.

4. Collaborate with HCFA, managed care associations and health plans to promote VCT for appropriate enrollees.

5. Work with health departments and community planning groups to increase funding appropriately for needed VCT services, and collaborate with other agencies (HCFA, HRSA, SAMHSA) to increase reimbursement to providers.

6. Work with other federal agencies (e.g., HRSA) and other health care providers (e.g., managed care) as well as professional organizations to increase provider recognition of primary HIV infection and awareness of other medical conditions that may also be indicative of HIV disease in order to promote appropriate testing.

7. Work with public and private health care entities to increase both provider-level and systems-level interventions to increase HIV testing. [Provider-level interventions include encouraging the use of electronic or other “passive” reminder systems (e.g., chart flags, reminder pop-ups on electronic medical record) to identify persons who would benefit from HIV testing or retesting. Systems-level interventions include increasing coverage of HIV testing as a health benefit.]

8. Collaborate with other agencies and partners (e.g., the private sector) to increase the availability of urine-based HIV testing that can be easily coupled with STD testing using the same specimen.
Objective 4: Increase the percentage of people who know their results after testing.

Strategies:
1. Support the use of rapid tests to provide same-day screening results as well as other mechanisms to reduce turnaround time for results (e.g., saliva and urine tests).
2. Evaluate and monitor grantees’ rates of client return to receive test results and work with grantees to increase rates of return if necessary.
3. Determine the effect of patient incentives and other strategies on increasing return rates.
4. Evaluate the impact of various forms of pre-test counseling on client satisfaction and return rates of sero-positives; provide guidance regarding optimal counseling content, delivery, messenger and context in order to increase return rates.
5. Increase follow-up for sero-positives who don’t return for their results, including pregnant women in antenatal settings.
Goal 3

Increase the proportion of HIV-infected people in the United States who are linked to appropriate care, prevention services and treatment services from an estimated 50% to 80%.

Objectives – Rank-Ordered Priority – Objectives are ranked from high (1) to lower (11) priority. Even lower priority objectives are considered important elements of comprehensive HIV prevention, and will not be eliminated from the array of CDC-sponsored activities. However, lower priority objectives may not receive supplementary or new resources.

1. Work with public health, the private medical sector, HRSA and other partners to reduce the disparities in access to prevention and care services that are experienced by communities of color and by women.

2. Work with public health, the private medical sector and other partners (e.g., SAMHSA, HRSA) to increase the percentage of persons who have been diagnosed with HIV who are successfully linked to culturally competent, science-based behavioral prevention services (safer sex, substance use, needle hygiene, partner services, STD symptoms and management, adherence to treatment) beyond post-test counseling.

3. Work with public health, the private medical sector, HRSA and other partners to increase the percentage of persons diagnosed with HIV who are successfully linked to care within 3 months of learning their HIV status or of being re-identified as being HIV-infected but out of care.

4. In collaboration with federal, state and local criminal justice systems, increase the percentage of correctional facility detainees (incarcerated for at least 30 days) identified as HIV-infected who are provided HIV prevention, treatment and care services and who, upon release, are successfully linked to those services in the community to which they return.

5. Work with public health, the private medical sector, HRSA and other partners to increase the proportion of HIV care providers offering routine, periodic STD screening and treatment to HIV-infected clients.

6. Work with public health, the private medical sector, HRSA and other partners to increase the proportion of HIV care providers offering routine, periodic TB screening and treatment to HIV-infected clients.
7. Work with public health, the private medical sector, HRSA and other partners to increase the proportion of HIV-infected persons who have a comprehensive, culturally competent, individualized assessment of their need for social, mental health, substance abuse treatment and behavioral prevention services, as well as medical care and treatment services, within 6 weeks of being identified as HIV-infected.

8. Work with public health, the private medical sector, HRSA and other partners to increase the proportion of persons diagnosed with HIV who need social and mental health services who are successfully linked to those services.

9. Work with public health, the private medical sector, HRSA, SAMHSA and other partners to increase the proportion of persons diagnosed with HIV who need substance abuse treatment services who are successfully linked to those services.

10. Through collaborative research, advocacy and facilitation, integrate optimal prevention services, including adherence to treatment, for persons with HIV and AIDS into the delivery of patient care in both public and private sectors.

11. Collaborate with other agencies and providers directly responsible for patient care to promote the optimal level of medical services for patients diagnosed with HIV to benefit individual health and reduce the likelihood of further transmission of HIV.
Rationale

All infected people – regardless of when in the course of their illness they become aware they have HIV – are included in the following objectives and strategies. Clearly, it is ideal for people to begin treatment as soon as possible after infection. But many people live far from the ideal, and may be infected for some time before seeking treatment and prevention services. The tactics to reach those who are newly infected and those who have been living with infection but have been out of care are different, and are described differently in the following objectives and strategies. While the tactics are different, what is similar is the universal requirement that CDC coordinate and collaborate with other public health agencies, such as the Health Resources Services Administration, Health Care Financing Administration and the Substance Abuse and Mental Health Services Administration, as well as other federal partners, and with the private medical sector, to achieve the objectives and strategies for this goal.

The goal also seeks to address two complementary but distinct types of services for people infected with HIV – services directed toward supporting their efforts to prevent further transmission and services directed toward their care and treatment. Setting separate objectives for each set of services highlights the difference in CDC’s role. Prevention services must be made an integral part of care, and linking people into care and treatment goes beyond medical care to the comprehensive care necessary for an infected individual that will support prevention efforts.

CDC does not have responsibility for care for infected individuals. CDC is responsible, however, for HIV prevention and for preventing HIV-associated morbidity and mortality. Thus, many of the objectives and strategies that follow call for CDC to coordinate with other agencies whose chief responsibilities are care, in order to institute the ongoing counseling and prevention messages that are needed throughout care. Recent outbreaks of syphilis and gonorrhea among HIV-infected MSM and evidence that some HIV-infected patients on multi-drug therapy are reverting to unsafe sex practices attest to the importance of ongoing prevention for HIV-infected individuals and suggest that prevention is likely to be an efficient use of resources to prevent HIV transmission as well as to keep HIV-infected people healthy.

Effective prevention efforts must address the spectrum of needs of those who are infected. An individual’s HIV status, while important from a public health perspective, may not be a top priority for the infected person. Care for HIV-infected people must be comprehensive, and reflect the fact that counseling for mental health, substance abuse and social service needs and linkage to required services helps the prevention effort and is also the right thing to do.
Objectives and Strategies – Objectives are ranked from high (1) to lower (11) priority. Even lower priority objectives are considered important elements of comprehensive HIV prevention, and will not be eliminated from the array of CDC-sponsored activities. However, lower priority objectives may not receive supplementary or new resources. Strategies are rank-ordered in terms of their priority.

Objective 1: Work with public health, the private medical sector, HRSA and other partners to reduce the disparities in access to prevention and care services that are experienced by communities of color and by women.

Strategies:
1. Collaborate with HRSA, NIH, the affected communities and other partners to develop and implement a comprehensive research agenda, involving the HIV-infected populations to be studied, that identifies and addresses health seeking, sociocultural, economic and service system barriers that impede linkages to prevention services, particularly for communities of color and women.
2. Promote cultural and linguistic competence in CDC-funded prevention programs.
3. Build the capacity of prevention providers serving HIV-infected persons of color to deliver culturally competent prevention services.
4. Develop and test innovative strategies to enhance referral and comprehensive treatment programs for drug-using pregnant women.
5. Collaborate with AHRQ, NIH and other partners to develop the capacity for persons of color and women to submit proposals to CDC, AHRQ and NIH that address research on HIV-infected minorities and women.

Objective 2: Work with public health, the private medical sector and other partners (e.g., SAMHSA, HRSA) to increase the percentage of persons who have been diagnosed with HIV who are successfully linked to culturally competent, science-based behavioral prevention services (safer sex, substance use, needle hygiene, partner services, STD symptoms and management, adherence to HIV treatment) beyond post-test counseling.

Strategies:
1. Assure that HIV-infected persons tested in CDC-funded sites obtain a comprehensive prevention assessment and appropriate referral to prevention case management (PCM) within 3 months of learning their HIV status.
2. Collaborate with HRSA to encourage the establishment and maintenance of prevention service components in public HIV/AIDS outpatient clinics.
3. Through technical assistance and collaboration with other partners, increase the capacity of HIV care providers (physicians, physician assistants, nurses in public and private settings) to provide brief behavioral prevention counseling to HIV-infected persons and to refer them to community-based organizations for further counseling as needed.
4. Work with HRSA and others partners to develop approaches to monitoring HIV-infected
patients’ linkage to prevention services.
5. Collaborate with other federal agencies and private health care providers to integrate HIV prevention services into public and private health care facilities that serve persons with HIV/AIDS, including the incorporation of performance measures into managed care contracts.
6. Increase the capacity of religious organizations to provide HIV prevention and support services for people with HIV/AIDS.
7. Promote the benefits of and provide technical assistance to large employers and employee health benefit purchasing coalitions to include language on HIV prevention in their managed care contracts.
8. Encourage organizations that accredit and license hospitals, correctional facility medical units and other health care facilities to incorporate HIV prevention policies into their accreditation standards.

Objective 3: Work with public health, the private medical sector, HRSA and other partners to increase the percentage of persons diagnosed with HIV who are successfully linked to care within 3 months of learning their HIV status or re-identified as being HIV-infected but out of care.

Strategies:
1. Publish guidelines for best practices for enhancing successful linkage from post-test counseling to care and patient use of recommended medical services.
2. Collaborate with HRSA and NIH to conduct research to determine the extent to which newly diagnosed HIV-infected persons successfully receive initial medical evaluation and to identify methods of enhancing linkage to care.
3. Collaborate with HRSA and other partners to conduct research to determine why previously diagnosed but currently out of care persons did not initially access or remain in medical care, and develop interventions to enhance linkage to care.
4. Develop a system to measure and monitor the linkage of HIV-infected persons from CDC-funded counseling and testing sites into care.

Objective 4: In collaboration with federal, state and local criminal justice systems, increase the percentage of correctional facility detainees (incarcerated for at least 30 days) identified as HIV-infected who are provided HIV prevention, treatment and care services and who, upon release, are successfully linked to those services in the community to which they return.

Strategies:
1. Through collaboration with correctional facilities, public health and other agencies (e.g., HRSA), promote comprehensive HIV needs assessments for HIV-infected detainees and the provision of services indicated to prevent HIV and associated diseases such as TB, hepatitis C and other communicable diseases.
2. Through collaboration, promote programs to provide culturally competent pre-release discharge planning and linkage to community-based organizations for follow-up and case management services.

3. Provide resources and support for public health agencies and/or directly funded community organizations to assure that identified HIV-infected persons released from correctional facilities are successfully linked to ongoing prevention, care, mental health, substance abuse and community services within their communities.

4. Provide resources and/or support to public health and criminal justice agencies and CBOs to facilitate access to education, counseling and testing and early intervention services for identified HIV-infected individuals in alternative sanction programs (e.g., drug courts) and probation programs.

5. In collaboration with partners, increase support for HIV-related services for inmates by demonstrating to key public health, criminal justice and community policy makers the economic, individual and public health benefits of preventing, identifying and treating HIV, STD and TB among incarcerated populations.

6. Evaluate the extent of provision of HIV prevention services to incarcerated persons and linkage of inmates to prevention and care services upon release.

**Objective 5:** Work with public health, the private medical sector, HRSA and other partners to increase the proportion of HIV care providers offering routine, periodic STD screening and treatment to HIV-infected clients.

**Strategies:**

1. Collaborate with HRSA, SAMHSA, Infectious Disease Society of America, other partners, agencies and organizations to increase awareness of HIV prevention providers of how STDs impact health and increase the probability of HIV transmission and acquisition and how to appropriately test and care for patients with STDs.

2. Increase the percentage of primary care providers for people with HIV who perform initial as well as ongoing, periodic risk assessment and STD screening and ongoing treatment as part of routine clinical care for HIV-infected persons in public, private and correctional settings.

3. Increase the number of HIV counseling and testing sites offering voluntary STD screening.

4. Increase awareness among people living with HIV of how STDs impact health and increase the probability of HIV transmission and acquisition.

5. Increase access to STD clinical care for people at increased risk for HIV and STDs by expanding service delivery venues to community-based organizations and non-traditional venues.

6. Better define the incidence of curable STDs in HIV-infected persons; assess extent to which current STD screening and treatment guidelines are being followed, and develop and issue recommendations on the frequency of screening HIV-infected persons for those STDs.

7. Recommend that all clinics counsel or refer for prevention counseling and partner counseling and referral services all HIV-infected persons who are diagnosed with a new STD.
Objective 6: Work with public health, the private medical sector, HRSA and other partners to increase the proportion of HIV care providers offering routine, periodic TB screening and treatment to HIV-infected clients.

Strategies:
1. Collaborate with HRSA, SAMHSA, Infectious Disease Society of America, American Lung Association, other partners, agencies and organizations to increase awareness of HIV care providers of how TB impacts health of patients with HIV disease.
2. Increase the percentage of primary care providers for people with HIV who perform TB screening and ongoing treatment as part of routine clinical care for HIV-infected persons in public, private and correctional settings.
3. Increase awareness among people living with HIV of how TB impacts the health of people with HIV disease.

Objective 7: Work with public health, the private medical sector, HRSA and other partners to increase the proportion of HIV-infected persons who have a comprehensive, culturally competent, individualized assessment of their need for social, mental health, substance abuse treatment and behavioral prevention services, as well as medical care and treatment services, within 6 weeks of being identified as HIV-infected.

Strategies:
1. Conduct research and demonstration programs to develop, implement and evaluate models and best practices for conducting HIV prevention case management needs assessment, including the need for ongoing integrated services such as mental health or substance abuse treatment and social services.
2. In conjunction with public and private sector partners, develop, disseminate and evaluate guidelines for conducting HIV prevention case management needs assessment.
3. Build capacity of CDC-supported HIV prevention counselors to conduct prevention case management needs assessments.
4. In conjunction with public and private sector partners, develop, implement and evaluate training programs to promote effective implementation of prevention case management needs assessment guidelines.

Objective 8: Work with public health, the private medical sector, HRSA and other partners to increase the proportion of persons diagnosed with HIV who need social and mental health services who are successfully linked to those services.

Strategies:
1. Increase capacity of CDC-supported HIV prevention counselors to link clients to social and mental health services.
2. Facilitate peer-to-peer technical assistance between states and regions that need assistance in developing programs for clients who need social and mental health services as part of their HIV prevention portfolio.
3. Collaborate with SAMHSA and other partners to increase the number of community coalitions that work on mental health, HIV prevention, HIV care and substance abuse issues to develop systems for broadening and referring newly diagnosed HIV-infected persons into appropriate social or mental health services.

4. Collaborate with SAMHSA and other federal agencies to promote the availability of services to those within the purview of the justice system.

5. Collaborate with SAMHSA to increase the availability of prevention services within culturally competent mental health services appropriate for age, gender and education level for people with both HIV disease and mental health disorders.

Objective 9: Work with public health, the private medical sector, HRSA, SAMHSA and other partners to increase the proportion of persons diagnosed with HIV, including pregnant women, who need substance abuse treatment services who are successfully linked to those services.

Strategies:

1. Collaborate with HRSA, SAMHSA and other prevention partners to develop, implement and evaluate the effectiveness of different approaches for successfully linking HIV-infected persons to needed substance abuse treatment services.

2. Develop policies and support practices to assure that HIV Prevention Community Planning Groups (CPGs) effectively identify and collaborate with state and local substance abuse agencies and with activities and programs related to SAMHSA’s block grant programs to provide comprehensive integrated services to persons who need them.

3. Work with SAMHSA and others to develop approaches to monitoring linkage to substance abuse treatment services.

4. Collaborate with SAMHSA, HRSA and other partners to develop approaches to encourage women living with HIV who are pregnant and using illicit drugs to seek substance abuse treatment and prenatal care services.

5. Promote the use of best practices to involve drug users in the planning and implementation of programs designed for hard-to-reach drug users through emphasis on the participation of peers in delivering services to drug users, their sex partners and children.

6. Work with SAMHSA and state substance abuse agencies to integrate HIV and substance abuse prevention and treatment services.

7. Assist SAMHSA to estimate better the size of the treatment gap for illicit drug users.
Objective 10: Through collaborative research, advocacy and facilitation, integrate prevention services for persons diagnosed with HIV and AIDS into the delivery of patient care in both public and private sectors.

Strategies:
1. Collaborate with HRSA, HCFA (Medicaid, Medicare and SCHIP), SAMHSA and the Department of Justice to develop and evaluate models for integrating ongoing prevention, care, treatment and other support services for HIV-infected persons.
2. Work with HRSA, community planning groups and state AIDS directors to incorporate appropriate care elements into prevention planning and prevention elements into Ryan White Planning Councils.
3. Collaborate with HRSA, HCFA and NIH to develop recommendations and a program for limited, targeted directly observed antiretroviral therapy (DOT) and DOT-friendly HAART plus OI prophylaxis regimens.
4. Develop epidemiologic tools that use HIV-related laboratory reporting for surveillance purposes, such as viral load, CD4+ and HIV resistance testing, to analyze patterns of HIV care delivery and HIV resistance to help target outreach to providers and patients.
5. Promote nationwide laboratory and provider-based HIV reporting.
6. Collaborate with HRSA to build prevention interventions into the professional training curricula and activities of HRSA’s AIDS Education and Training Centers.
7. In collaboration with other federal agencies, academic and professional organizations, seek incorporation of HIV prevention and treatment modules into medical and health sciences professional education.

Objective 11: Collaborate with other agencies and providers directly responsible for patient care to promote the optimal level of medical services for patients diagnosed with HIV to benefit individual health and reduce the likelihood of further transmission of HIV.

Strategies:
1. In collaboration with HRSA, HCFA and NIH, examine treatment patterns and characteristics of persons receiving and providers offering differing levels of treatment; use this information to provide guidance to practitioners concerning best practices and to develop recommendations for implementing care among diverse populations in order to achieve maximum individual and public health benefits from science-based treatments.
3. Continue to assess the utility of highly active antiretroviral therapy (HAART) as a means of preventing transmission of HIV and provide recommendations as needed.
Goal 4

Reduce HIV transmission and improve HIV/AIDS care and support through partnership with resource-constrained countries.

Objectives: Rank-Ordered Priority – Objectives are ranked from high (1) to lower (7) priority. Even lower priority objectives are considered important elements of comprehensive HIV prevention, and will not be eliminated from the array of CDC-sponsored activities. However, lower priority objectives may not receive supplementary or new resources.

1. Decrease sexually transmitted HIV infections.
2. Develop the capacity of partners in host countries for HIV prevention and care efforts.
3. Expand and strengthen HIV/STD/TB surveillance programs.
4. Improve basic scientific knowledge of HIV and the safety and efficacy of new technologies.
5. Decrease HIV infections from mother to child.
6. Increase access to improved HIV care and support.
7. Decrease parenterally transmitted HIV infections.
Rationale

The global AIDS epidemic is the moral, medical and political challenge of our time. Everyone, everywhere in the world, is affected by this crisis. And, while the epidemic is indeed global, it is composed of multiple, country-specific epidemics, which vary widely in their scope, their severity and their management. Each country’s environment – the epidemiologic situation, health system characteristics, donor resources and state capacity – is uniquely its own. Therefore, each country’s priorities will be uniquely its own. Likewise, intervention and research outcomes must be specific to country-level realities, so evaluation of outcomes and impacts will also be country-specific. Therefore, the objectives and strategies that follow are written broadly, to accommodate the unique needs of the various countries CDC and other governmental agencies (e.g., USAID) and non-governmental organizations (the World Bank, World Health Organization, Family Health International) partner with.

CDC has a long history of working successfully around the globe to address pressing health concerns, including HIV. The objectives and strategies to guide CDC’s involvement in addressing the global AIDS epidemic are defined by these basic philosophical commitments:

1. **Host-country involvement**: Each partner country must have local ownership of and leadership in collaborative projects; there must be serious CDC commitment to in-country capacity building; and partner countries must play an active role in the conceptualization, implementation and evaluation stages of research and prevention projects.

2. **Destigmatization of HIV in society**: The efficacy of the recommended research and prevention strategies will be severely limited unless implemented in the context of destigmatizing HIV in partner countries.

3. **Designing research and programs with sensitivity to gender, culture and age**: Women, youth and other critical groups must participate in defining their needs, priorities, program and in addressing barriers to their health and empowerment.

4. **Consideration of human rights**: It is essential that the principles outlined in the United Nations Declaration of Human Rights are observed for each of the suggested strategies. There must be an increased awareness of and response to the tremendous barriers that exist to accessing expensive technologies such as diagnostics, drugs and information.

5. **Leadership**: It is critical that leadership of partner countries, the United States and other donor countries continue to acknowledge the importance of the HIV epidemic and actively support HIV research and prevention activities.
Objectives and Strategies – Objectives are ranked from high (1) to lower (7) priority. Even lower priority objectives are considered important elements of comprehensive HIV prevention, and will not be eliminated from the array of CDC-sponsored activities. However, lower priority objectives may not receive supplementary or new resources. Strategies are rank-ordered in their priority.

Objective 1: Decrease sexually transmitted HIV infections.

Strategies:
1. Develop and evaluate behavioral interventions to reduce the risk of acquiring or transmitting HIV and other STDs, particularly for sex workers and their clients, displaced populations, in- and out-of-school youth, those in the workplace and for other locally relevant populations.
2. Expand voluntary counseling and testing for HIV.
3. Investigate the most effective intervention methods to address the role of STDs in HIV transmission and acquisition in a range of epidemiologic settings and to improve STD treatment services.
4. Implement prevention marketing programs for the general population.
5. Expand interventions for the prevention of sexually acquired HIV infections in women and in men, including MSM.

Objective 2: Develop the capacity of partners in host countries for HIV prevention and care efforts.

Strategies:
1. Work with partner country governments and communities to strengthen their capacity in the planning, implementation, evaluation, and monitoring of HIV intervention programs.
2. Work with communities in partner countries to decrease the stigma of HIV infection.
3. Build partners’ capacity to develop, review and implement scientific and operational research protocols according to internationally accepted bioethical precepts.
4. Build the capacity of partner countries to procure and distribute antiretroviral drugs and other HIV-related products.
5. Work with communities in partner countries to prepare for trials of candidate HIV vaccines and microbicides.

Objective 3: Expand and strengthen HIV/STD/TB surveillance programs.

Strategies:
1. Strengthen HIV sentinel serosurveillance programs to monitor epidemic trends.
2. Strengthen the collection and use of behavioral data.
3. Strengthen laboratory testing for HIV including the implementation of quality assurance programs.
4. Promote the use of surveillance data for public health decision-making.
5. Assess the quality of surveillance programs.

Objective 4: Improve basic scientific knowledge of HIV and the safety and efficacy of new technologies.

Strategies:
1. Evaluate the safety and efficacy of HIV vaccine candidates and vaginal microbicides and apply this knowledge in the field.
2. Conduct and apply HIV virologic research, focusing on the epidemiology, ecology and evolutionary biology of HIV infection.
3. Conduct HIV vaccine and microbicide preparedness work, including the development of relevant cohorts.
4. Evaluate and apply new laboratory tests for HIV diagnostics.

Objective 5: Decrease HIV infections from mother to child.

Strategies:
1. Expand access to VCT services for antenatal women during the prenatal period and/or at the time of delivery.
2. Conduct research on improving biomedical and behavioral methods to interrupt mother-to-child transmission in the prenatal, perinatal and postnatal periods; apply results to the field.
3. Expand access to antiretroviral drugs for HIV-infected pregnant women and their newborns.
4. Provide appropriate breast-feeding alternatives to HIV-infected women.
5. Study postnatal prophylactic and early weaning strategies to decrease breastfeeding transmission among HIV-infected women who choose to breastfeed.
6. Strengthen family planning services to expand options for HIV-infected women.

Objective 6: Increase access to improved HIV care and support.

Strategies:
1. Strengthen VCT programs to make critical linkages to care and support programs.
2. Work with communities to decrease stigma among HIV-infected persons.
3. Expand and strengthen programs that prevent and treat tuberculosis and other opportunistic infections in HIV-infected persons.
4. Conduct and apply research on the clinical management of HIV, including the prevention and treatment of opportunistic infections and cancers, in hospital, home and community settings.
5. Conduct and apply research on the psychological and social needs of people living with HIV/AIDS and people affected by AIDS.
6. Promote availability and affordability of AIDS control technologies such as diagnostics, antiretroviral drugs and therapies.
7. Conduct and apply research on the safety and efficacy of antiretroviral therapy.

Objective 7: Decrease parenterally transmitted HIV infections.

Strategies:
1. Strengthen capacity of countries to provide sufficient safe blood for transfusion.
2. Conduct and apply research on behavioral change methodologies, including targeted harm reduction programs, to prevent IDU-related transmission.
3. Strengthen the capacity of health care workers to prevent parenteral HIV infection to themselves and to patients.
Appendix A

Background Information on the Strategic Planning Process

In November 1998, CDC initiated a detailed review of its HIV/AIDS prevention activities. The overall purpose of this review was to identify HIV prevention program gaps and shortfalls. The process was co-led by the National Center for HIV, STD, and TB Prevention (NCHSTP) and the Office of Program Planning and Evaluation (OPPE) within the CDC Director’s Office. The process was internal until June 1999, when the internal review was augmented by the formation of an external work group, composed of members of NCHSTP’s Advisory Committee for HIV and STD Prevention and other outside experts. One of the chief recommendations of this group was that CDC develop a national plan for HIV/AIDS prevention.

On February 2-3, 2000, the first meeting to develop a comprehensive national plan for HIV/AIDS prevention, spanning all centers and HIV planning activities of CDC, was convened in Atlanta. Participants consisted of external collaborative partners, expert academicians, clinicians and organizational representatives. The external consultants were aided by a diverse group of CDC staff from all CIOs (Centers, Institute and Offices) with HIV responsibilities and activities. A list of the planning workgroup members is in Appendix B, page 57.

External and internal participants broke into four workgroups and were charged with developing and prioritizing objectives and strategies to meet CDC’s three domestic goals and one international goal.

The workgroups were not asked to develop specific action steps to implement proposed strategies. These will be developed by CDC. However, based on their wide-ranging expertise, several workgroups suggested action steps, which are currently under consideration by CDC.

Each workgroup was chaired by an external consultant and co-chaired by a senior CDC staff person. Between February and April the workgroups held five face-to-face meetings and had 16 telephone conference calls to develop and refine their goals and to develop objectives and strategies to achieve the goals. An electronic bulletin board was established to share drafts of individual workgroup efforts, CDC guidance and other information pertinent to HIV and to strategic planning.

In April CDC held meetings with each of the four workgroups to evaluate their draft work plans. Gaps, omissions, overlaps and ambiguities were identified and discussed. Groups were requested to revise their plans based on the CDC input. Groups were also requested to prioritize their objectives and strategies. The following criteria for prioritizing objectives and strategies were provided by CDC:

- Impact on HIV transmission and/or acquisition. That is, the activity’s impact on reducing HIV infections.

- Impact on the current (and projected) state of the epidemic. That is, extent to which this activity addresses populations at risk for infection or already infected.

- Scientific currency of the activity. That is, the degree to which the activity reflects the most up-to-date behavioral, biomedical, communications or other science.
Groups were also provided three alternative methods for applying these criteria to prioritize objectives and strategies.

Following revisions, the workgroups met in Atlanta on May 2-3, 2000, to present their draft workplans to each other and to a broader CDC audience for feedback. Based on this feedback, final workgroup plans for the four CDC goals were developed. Each workgroup prioritized its objectives and strategies as described at the beginning of each section detailing objectives and strategies for each of the four goals.
Appendix B

Workgroup 1: Decrease New Infections

Chair
Mr. Alan Nyitray, MS
Director of Prevention Services
Southern Arizona AIDS Foundation
375 South Euclid
Tucson, AZ 85719
Phone: 520-628-7223
Fax: 520-628-7222
Email: prevention@SAAF.org

CDC Co-chair
David Holtgrave, PhD
Division of HIV/AIDS Prevention-Intervention, Research and Support
National Center for HIV, STD, and TB Prevention
1600 Clifton Rd., NE (E35)
Atlanta, GA 30333
Phone: 404-639-5200
Fax: 404-639-0897
Email: dyh6@cdc.gov

Members
Sevgi Aral, PhD
Division of STD Prevention
National Center for HIV, STD, and TB Prevention
1600 Clifton Rd., NE (E02)
Atlanta, GA 30333
Phone: 404-639-8259
Fax: 404-639-8608
Email: soa1@cdc.gov

Ignatius Bau, JD
Policy Director
Asian and Pacific Islander American Health Forum
942 Market Street, Suite 200
San Francisco, CA 94102
Phone: 415-954-9951
Fax: 415-954-9999
Email: ibau@apiahf.org

Guthrie S. (Gus) Birkhead, MD, MPH
Director, AIDS Institute
New York State Department of Health
Room 412, Corning Tower, Empire State Plaza
Albany, NY 12237
Phone: 518-473-7542
Fax: 518-486-1315
Email: gsb02@health.state.ny.us

Stephen J. Blumberg, PhD
National Center for Health Statistics
6525 Belcrest Rd., Room 850 (P-08)
Hyattsville, MD 20782
Phone: (301) 458-4107
Fax: (301) 458-4035
Email: sbw5@cdc.gov

Bernard Branson, MD
Division of HIV/AIDS Prevention Intervention Research and Support
1600 Clifton Rd., NE (E-46)
Atlanta, GA 30333
Phone: 404-639-6166
Fax: 404-639-2029
Email: bmb2@cdc.gov

Thomas Coates, PhD
Director
Center for AIDS Prevention Studies and AIDS Research Institute
University of California, San Francisco
74 New Montgomery Street, Suite 600
San Francisco, CA 94105
Phone: 415-597-9157
Fax: 415-597-9213
Email: tcoates@psg.ucsf.edu
Gary Edgar, BA
Division of HIV/AIDS Prevention-Surveillance and Epidemiology
National Center for HIV, STD, and TB Prevention
1600 Clifton Rd., NE (E-45)
Atlanta, GA 30333
Phone: 404-639-2057
Fax: 404-639-2029
Email: gwe1@cdc.gov

Aida L. Giachello, PhD
Center Director and Associate Professor
Midwest Latino Health, Research, Training, & Policy Center
1640 West Roosevelt
Suite 636 IIDD M/C 625
Chicago, IL 60608-6906
Phone: 312-413-1952
Fax: 312-996-3212
Email: aida@uic.edu

Ms. Janice M. Huy, MS
National Institute for Occupational Safety and Health
4676 Columbia Parkway (R-12)
Cincinnati, OH 45226
Phone: (513) 841-4245
Fax: (513) 841-4483
Email: jmh4@cdc.gov

Laura Kann, PhD
National Center for Chronic Disease Prevention and Health Promotion
Division of Adolescent and School Health
1600 Clifton Rd., NE (K-33)
Atlanta, GA 30333
Phone: 770-488-3202
Fax: 770-488-3112
Email: lkk1@cdc.gov

Kent Klindera, MPH
Director, Targeted HIV/STD Interventions
Advocates for Youth
1025 Vermont Avenue NW
Suite 200
Washington, DC 20005
Phone: 202-347-5700 x 31
Fax: 202-347-2263
Email: kent@advocatesforyouth.org

Jean McGuire, PhD, MPH
Director, HIV/AIDS Bureau
Massachusetts Department of Public Health
250 Washington Street, 3rd Floor
Boston, MA 02108-4619
Phone: 617-624-5303
Fax: 617-624-5399
Email: jean.mcguire@state.ma.us

Steve Morin, PhD
Center for AIDS Prevention Studies
University of California, San Francisco
74 New Montgomery Street, Suite 600
San Francisco, CA 94105
Phone: 415-597-9157
Fax: 415-597-9213
Email: smorin@psg.ucsf.edu

Mr. Matthew Murguía
Associate Director for Policy
White House Office of Nat’l AIDS Policy
736 Jackson Place, NW
Washington, DC 20503
Phone: 202-456-2437
Fax: 202-456-2438
Email: mmurguia@opd.eop.gov

Ann O’Leary, PhD
Division of HIV/AIDS Prevention-Intervention, Research and Support
National Center for HIV, STD, and TB Prevention
1600 Clifton Rd., NE (E37)
Atlanta, GA 30333
Phone: 404-639-1931
Fax: 404-639-1950
Email: aao0@cdc.gov
Margaret Scarlett, DMD
Senior Policy Analyst
Office of HIV/AIDS Policy
200 Independence Avenue
Room 733 E
Washington, DC 20201
Phone: 202-401-7945
Fax: 202-690-7560
Email: mscarlett@osophs.dhhs.gov

Mr. Harry Simpson
Executive Director
Community Health Awareness Group
3028 East Grand Boulevard
Detroit, MI 48202
Phone: 313-872-2424
Fax: 313-872-5546
Email: Harry1081@aol.com

Mr. Carlos Vega-Matos
Director
HIV Prevention/Healthy Schools Project
National Association of State Boards of Education
277 South Washington Street, Suite 100
Alexandria, VA 22314
Phone: 703-684-4000, ext. 110
Fax: 703-836-2313
Email: carlosv@nasbe.org

Mr. Andrew Woods
321 Holcomb Street
Hartford, CT 06112
Phone: 860-543-9717
Fax: 860-219-0538
Email: awoods3976@aol.com

Pascale Wortley, MD, MPH
Division of HIV/AIDS Prevention-Surveillance and Epidemiology
National Center for HIV, STD, and TB Prevention
1600 Clifton, Rd., NE (E-47)
Atlanta, GA 30333
Phone: 404-639-4497
Fax: 404-639-2029
Email: pmw1@cdc.gov

Linda Wright-Deaguero, PhD, MPH
Epidemiology Program Office
1600 Clifton Rd., NE (K-73)
Atlanta, GA 30333
Phone: 770-488-8232
Fax: 770-488-8462
Email: lkwl@cdc.gov

CDC Liaisons
Janet Cleveland, MS
Division of HIV/AIDS Prevention-Intervention, Research, and Support
National Center for HIV, STD, and TB Prevention
1600 Clifton Rd., NE (E-35)
Atlanta, GA 30333
Phone: 404-639-5200
Fax: 404-639-0897
Email: jcc9@cdc.gov

Ken Rose, MPA
National Center for Chronic Disease Prevention and Health Promotion
Division of Adolescent and School Health
1600 Clifton Rd., NE (K-29)
Atlanta, GA 30333
Phone: 770-488-3254
Fax: 770-488-3110
Email: kfr2@cdc.gov
Workgroup 2: Increase Knowledge of Serostatus

Chair
**Mr. Cornelius Baker**
Executive Director
Whitman-Walker Clinic
1407 S Street SW
Washington, DC 20009
Phone: 202-797-3511
Fax: 202-797-0242
Email: cbaker@wwc.org

CDC Co-chair
**Harold Jaffe, MD**
National Center for Infectious Diseases
1600 Clifton Rd., NE (A-12)
Atlanta, GA 30333
Phone: 404-639-4581
Fax: 404-639-4664
Email: hwj1@cdc.gov

Members
**Lynn Austin, MPA**
Division of HIV/AIDS Prevention-Intervention, Research and Support
National Center for HIV, STD, and TB Prevention
1600 Clifton Rd., NE (E-35)
Atlanta, GA 30333
Phone: 404-639-5200
Fax: 404-639-0897
Email: laa2@cdc.gov

**Michelle Bonds, BA**
National Center for HIV, STD, and TB Prevention-Office of Communications
1600 Clifton Rd., NE (E-06)
Atlanta, GA 30333
Phone: 404-639-8028
Fax: 404-639-8910
Email: meb0@cdc.gov

**Lawrence S. Brown, MD, MPH**
Urban Resource Institute
Addiction Research and Treatment Corporation
22 Chapel Street
Brooklyn, NY 11201
Phone: 718-260-2917
Fax: 718-522-3186
Email: lbrown@artcny.org

**Ms. Gail M. Curtis**
Acting Executive Director
Health Watch
3020 Glenwood Road
Brooklyn, NY 11210
Phone: 718-434-5411
Fax: 718-434-5048
Email: HealthWatc@aol.com

**Ann Duerr, PhD**
Division of Reproductive Health
National Center for Chronic Disease Prevention and Health Promotion
1600 Clifton Road, NE (K34)
Atlanta, GA 30333
Phone: 770-488-5250
Fax: 770-488-5965
Email: axd9@cdc.gov

**Donna Futterman, MD**
Associate Professor of Pediatrics
Director, Adolescent AIDS Project
Montefiore Medical Center
111 East 210 Street
Bronx, NY 10467
Phone: 718-882-0322
Fax: 718-882-0432
Email: futterma@aecom.yu.edu
Thomas L. Hearn, PhD  
Public Health Practice Program Office  
1600 Clifton Rd., NE (G-23)  
Atlanta, GA 30333  
Phone: 770-488-8093  
Fax: 770-488-8275  
Email: tlh1@cdc.gov

John Jemmott III, PhD  
Kenneth B. Clark Professor of Communication  
University of Pennsylvania  
Annenberg School for Communication  
3535 Market Street, Suite 520  
Philadelphia, PA 19104-3309  
Phone: 215-573-9500  
Fax: 215-573-9303  
Email: jjemmott@asc.upenn.edu

CAPT Newton E. Kendig II, MD  
Medical Director  
Health Services Division  
federal Bureau of Prisons  
320 First Street NW  
Washington, DC 20534  
Phone: 202-307-3055  
Fax: 202-307-0826  
Email: nkendig@bop.gov

John Ludden, MD  
Associate Clinical Professor  
Harvard Medical School  
126 Brookline Avenue, Suite 200  
Boston, MA 02215  
Phone: 617-421-6219  
Fax: 617-859-8112  
Email: healthcare@ludden.net

Gerry McQuillan, PhD  
National Center for Health Statistics  
6525 Belcrest Rd., Room 1000 (P-08)  
Hyattsville, MD 20782  
Phone: (301) 458-4371  
Fax: (301) 458-4368  
Email: gmm2@cdc.gov

Frank Oldham, Jr.  
Assistant Commissioner  
Chicago Department of Public Health  
333 South Street, 2nd Floor  
Chicago, IL 60604  
Phone: 312-745-0384  
Fax: 312-747-9663  
Email: oldham_frank@cdph.org

James Pearson, DrPH, BCLD  
DGS Deputy Director  
Division of Consolidated Laboratory Services  
Commonwealth of Virginia  
P.O. Box 1877  
Richmond, VA 23215  
Phone: 804-786-7905  
Fax: 804-371-7973  
Email: jpearson@dgs.state.va.us

Walter Shervington, MD  
President, National Medical Association  
CEO, New Orleans Adolescent Hospital  
210 State Street  
New Orleans, LA 70122  
Phone: 504-897-4616  
Fax: 504-896-4959  
Email: wwsmd9@pol.net

Kathy Sikkema, PhD  
Associate Professor  
Yale University School of Medicine  
The Consultation Center  
389 Whitney Avenue  
New Haven, CT 06511  
Phone: 203-789-7645  
Fax: 203-562-6355  
Email: kathleen.sikkema@yale.edu

Liza Solomon, DrPH  
Director for AIDS Administration  
State of Maryland  
500 North Calvert Street, 5th Floor  
Baltimore, MD 21202
Phone: 410-767-5013
Fax: 410-333-6333
Email: solomonl@dhmh.state.md.us
CDC Liaisons

Consuelo Beck-Sague, MD
Division of Reproductive Health
National Center for Chronic Disease
Prevention and Health Promotion
1600 Clifton Road, NE (K34)
Atlanta, GA 30333
Phone: 770-488-
Fax: 770-488-
Email: cmb1@cdc.gov

Rich Wolitski, MA
Division of HIV/AIDS Prevention-Intervention, Research, and Support
National Center for HIV, STD, and TB Prevention
1600 Clifton Rd., NE (E-35)
Atlanta, GA 30333
Phone: 404-639-1939
Fax: 404-639-1950
Email: rywl@cdc.gov
Workgroup 3: Increase Access to Prevention Services and Linkages to Care

Chair
Mike Isbell, JD
President
Mike Isbell Consulting, Inc.
304 Park Avenue South, 11th Floor
New York, NY 10010
Phone: 212-590-2465
Fax: 212-590-2310
Email: mtisbell@aol.com

CDC Co-chair
Kathy Rauch, BA
Division of HIV/AIDS Prevention-Intervention Research and Support
1600 Clifton Rd., NE (D-21)
Atlanta, GA 30333
Phone: 404-639-4675
Fax: 404-639-0910
Email: kjr1@cdc.gov

Members
Paul Arons, MD
Medical Director
Bureau of HIV/AIDS
Florida Department of Health
2020 Capitol Circle SE
Mailbin A09
Tallahassee, FL 32399-1715
Phone: 850-245-4488
Fax: 850-414-6719
Email: paul_arons@doh.state.fl.us

William Cunningham, MD, MPH
Assistant Professor of Medicine and Public Health
UCLA
10833 Le Conte Avenue
Room 31-245A CHS
Los Angeles, CA 90095-1772
Phone: 310-206-1632
Fax: 310-825-3317
Email: wcunningham@mednet.ucla.edu

Carlos Del Rio, MD
Associate Professor of Medicine
Emory University School of Medicine
69 Butler Street, SE
Atlanta, GA 30303
Phone: 404-616-4634 (Secretary ext. 6145)
Fax: 404-880-9305
Email: cdelrio@emory.edu

Robert Fullilove, EdD
Associate Dean for Community and Minority Affairs
Columbia University School of Public Health
600 West 168th Street
New York, NY 10032
Phone: 212-740-7292
Fax: 212-795-4222
Email: ref5@columbia.edu

Ms. Glenda Gardner
Bureau Chief
Bureau of HIV/STD Prevention
8000 North Stadium Drive, 5th Floor
Houston, TX 77054
Phone: 713-794-9164
Fax: 713-798-0830
Email: ggardner@hlt.ci.houston.tx.us

Samuel A. Bozzette, MD, PhD
Professor of Medicine/Senior Research Associate
University of California, San Diego
Veterans Administration Healthcare System
3350 La Jolla Village Drive, 111N-1
San Diego, CA 92161
Phone: 858-552-8585, x4324
Fax: 858-552-4321
Email: sbozzette@ucsd.edu
Julie L. Gerberding, MD  
National Center for Infectious Diseases  
1600 Clifton Rd., NE (A07)  
Atlanta, GA 30333  
Phone: 404-639-6400  
Fax: 404-639-6458  
Email: jyg2@cdc.gov

Mr. T. Randolph Graydon  
Director  
Division of Advocacy and Special Issues  
Center for Medicaid and State Operations  
Health Care Financing Administration  
7500 Security Boulevard  
MailStop S2-14-26  
Baltimore, MD 21244  
Phone: 410-786-1357  
Fax: 410-786-9004  
Email: RGraydon@hcfa.gov

Ms. Joan Holloway  
Deputy Associate Administrator  
Extramural Affairs  
HIV/AIDS Bureau  
Health Resources and Services Administration  
5600 Fishers Lane  
Parklawn Room 7-13  
Rockville, MD 20857  
Phone: 301-443-9530 or 7036  
Fax: 301-443-0055  
Email: jholloway@hrsa.gov

Ms. Miguelina Maldonado  
Director of Gov’t Relations and Policy  
National Minority AIDS Council  
1931 13th St., NW  
Washington, DC 20005  
Phone: 202-483-6622  
Fax: 202-483-1135  
Email: mmaldona@nmac.org

Gary Marks, PhD  
Division of HIV/AIDS Prevention-Surveillance and Epidemiology  
National Center for HIV, STD, and TB Prevention  
1600 Clifton Rd., NE (E-45)  
Atlanta, GA 30333  
Phone: 404-639-5261  
Fax: 404-639-6118  
Email: gdm8@cdc.gov

Chad Martin, MPH  
Division of HIV/AIDS Prevention-Intervention Research and Support  
1600 Clifton Rd., NE (E-35)  
Atlanta, GA 30333  
Phone: 404-639-5200  
Fax: 404-639-0897  
Email: cgm8@cdc.gov

M. Valerie Mills, MSW  
Associate Administrator  
HIV/AIDS Team  
Substance Abuse and Mental Health Services Administration  
5600 Fishers Lane  
Room 12C-15  
Rockville, MD 20857  
Phone: 301-443-0556  
Fax: 301-443-3817  
Email: vmills@samhsa.gov

Ms. Margaret Murray  
Director, Division of Medical Assistance and Health Services  
Department of Human Services  
7 Quakerbridge Plaza  
P.O. Box 712  
Trenton, NJ 08625-0712  
Phone: 609-588-2600  
Fax: 609-588-3538  
Email: mmurray@dhs.state.nj.us
Elena Rios, MD  
President  
National Hispanic Medical Association  
1411 K Street, NW  
Suite 200  
Washington, DC 20005  
Phone: 202-628-5895  
Fax: 202-628-5898  
Email: nhma@earthlink.net

Ms. Deborah Von Zinkernagel, RN  
Deputy Director for Policy  
Office of HIV/AIDS Policy, OPHS/HHS  
200 Independence Avenue  
Room 736 E  
Washington, DC 20201  
Phone: 202-690-5560  
Fax: 202-690-7560  
Email: DvonZinkernagel@osophs.dhhs.gov

George Schmid, MD, MSc  
Division of STD Prevention  
National Center for HIV, STD, and TB Prevention  
1600 Clifton Rd., NE (E27)  
Atlanta, GA 30333  
Phone: 404-639-8279  
Fax: 404-639-8609  
Email: gps1@cdc.gov

Carol Scotton, PhD  
Division of HIV/AIDS Prevention-Intervention, Research and Support  
National Center for HIV, STD, and TB Prevention  
1600 Clifton Rd., NE (E35)  
Atlanta, GA 30333  
Phone: 404-639-0901  
Fax: 404-639-0910  
Email: cxr3@cdc.gov

Greg Wood, MSN, FNP  
Director, Centers of Excellence-HIV Indian Health Service  
Phoenix Indian Medical Center  
4212 North 16th Street  
Phoenix, AZ 85016  
Phone: 602-263-1502  
Fax: 602-263-1624 or 1583  
Email: Greg.Wood@MAIL.IHS.GOV

CDC Liaisons  
Ken Hunt, BS  
Division of HIV/AIDS Prevention-Surveillance and Epidemiology  
National Center for HIV, STD, and TB Prevention  
1600 Clifton Rd., NE (E-46)  
Atlanta, GA 30333  
Phone: 404-639-2058  
Fax: 404-639-2029  
Email: kvh1@cdc.gov

Mary Vernon, MD, MPH  
National Center for Chronic Disease Prevention and Health Promotion  
Division of Adolescent and School Health  
4770 Buford Hwy NE (K-31)  
Atlanta, GA 30341  
Phone: 770-488-3253  
Fax: 770-488-3111  
Email: mev0@cdc.gov
Workgroup 4: International Prevention

Chair
Peter Lamptey, MD, DrPH
Senior Vice President
HIV/AIDS Prevention and Care Department
Family Health International
2101 Wilson Boulevard, Suite 700
Arlington, VA 22201
Phone: 703-516-9779
Fax: 703-516-9781
Email: plamptey@fhi.org

CDC Co-chair
Alan Greenberg, MD
Division of HIV/AIDS Prevention-Surveillance and Epidemiology
National Center for HIV, STD, and TB Prevention
1600 Clifton Rd., NE (E-45)
Atlanta, GA 30333
Phone: 404-639-6130
Fax: 404-639-6118
Email: aeg1@cdc.gov

Members
Jim Alexander, MD
Epidemiology Program Office
1600 Clifton Rd., NE (D-18)
Atlanta, GA 30333
Phone: 404-639-4242
Fax: 404-639-1362
Email: axj1@cdc.gov

Victor Barnes
Division of HIV/AIDS Prevention-Intervention, Research and Support
National Center for HIV, STD, and TB Prevention
1600 Clifton Road, NE (E35)
Atlanta, GA 30333
Phone: 404-639-5204
Fax: 404-639-5260
Email: vcb3@cdc.gov

Donald Burke, MD
Professor, Department of International Health
Johns Hopkins University
School of Public Health
Hampton House, Room 217
624 North Broadway
Baltimore, MD 21205
Phone: 410-614-5960
Fax: 410-502-6898
Email: dburke@jhsp.edu

Gambrill Hollister, MPH
National Center for Chronic Disease Prevention and Health Promotion
Division of Adolescent and School Health
1600 Clifton Rd., NE (K-29)
Atlanta, GA 30333
Phone: 770-488-3103
Fax: 770-488-3110
Email: geh8@cdc.gov

Jacob Gayle, PhD
Senior Technical Advisor
Joint United Nations Programme on HIV/AIDS (UNAIDS)
c/o The World Bank
1818 H Street, NW
Room G 3-042
Washington, DC 20433
Phone: 202-473-0393
Fax: 202-522-3234
Email: jgayle@worldbank.org

Debbie Jones, BS
Public Health Practice Program Office
1600 Clifton Rd., NE (G-23)
Atlanta, GA 30333
Phone: 770-488-2446
Fax: 770-488-2420
Email: dlj1@cdc.gov
Dick Keenlyside, MD  
National Center for HIV, STD, and TB Prevention  
1600 Clifton Road, NE (E07)  
Atlanta, GA 30333  
Phone: 404-639-8085  
Fax: 404-639-8600  
Email: dyk8@cdc.gov

Michael Qualls, MPH  
Global AIDS Activity  
1600 Clifton Rd., NE (E07)  
Atlanta, GA 30333  
Phone: 404-639-8321  
Fax: 404-639-8601  
Email: muq1@cdc.gov

Eve Lackritz, MD  
Division of HIV/AIDS Prevention-Surveillance and Epidemiology  
1600 Clifton Road, NE (E50)  
Atlanta, GA 30333  
Phone: 404-639-6100  
Fax: 404-639-4268  
Email: eal3@cdc.gov

Michael D. Sweat, PhD  
Assistant Professor, Department of International Health  
Johns Hopkins University  
School of Public Health  
615 North Wolfe Street, Room E7140  
Baltimore, MD 21250  
Phone: 410-614-4536  
Voicemail: 410-955-7159  
Fax: 703-995-0615  
Email: msweat@jhsph.edu

Ellen MacLachlan, MPH  
Division of STD Prevention  
National Center for HIV, STD, and TB Prevention  
1600 Clifton Rd., NE (E02)  
Atlanta, GA 30333  
Phone: 404-639-8312  
Fax: 404-639-8608  
Email: eew7@cdc.gov

Barbara O. de Zalduondo, PhD  
Senior Technical Advisor  
Division of HIV/AIDS USAID  
G/PHN/HN 3.07-18M  
3rd Floor, Ronald Reagan Building  
Washington, DC 20523-3700  
Phone: 202-712-1325  
Fax: 202-216-3046  
Email: bzalduondo@USAID.gov

Ms. Sheila Mitchell, MBA  
CDC Global AIDS Activity  
1600 Clifton Rd., NE (E07)  
Atlanta, GA 30333  
Phone: 404-639-8291  
Fax: 404-639-  
Email: swm0@cdc.gov

Alawode Oladele, MD, MPH  
President and CEO  
Premiere International Health Care Inc.  
PMB 333  
4426 Hugh Howell Road, Suite B  
Tucker, GA 30084  
Phone: 770-491-8667  
Fax: 770-491-8655  
Email: premierehealth@medscape.com

CDC Liaisons  
Kellie Lartigue  
Division of HIV/AIDS Prevention-Intervention, Research, and Support  
National Center for HIV, STD, and TB Prevention  
1600 Clifton Rd., NE (E-40)  
Atlanta, GA 30333  
Phone: 404-639-0977  
Fax: 404-639-0944  
Email: kel5@cdc.gov
Mark Rayfield, PhD
National Center for Infectious Diseases
1600 Clifton Rd., NE (A-12)
Atlanta, GA 30333
Phone: 404-639-3820
Fax: 404-639-4664
Email: mar3@cdc.gov